CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
[ADDRESS_96650]
IV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed 
Medications  
Protocol Number: Pending  
PI[INVESTIGATOR_88470]:  155481  
Principal Investigator:  [INVESTIGATOR_88471], MD, MHS  
Co-Principal 
Investigator /IND 
Sponsor : 
Data Coordinating 
Center Investigator  
Lead  
Funding Agency:  
Ve rs ion:  
Date:  Duke Clinical Research Institute 
[ADDRESS_96651]. 
Durham, NC [ZIP_CODE] 
Phone: 919-6 68-7515 
Email: adrian.hernandez@duke. edu 
Susanna Naggie, MD, M HS 
Duke Clinical Research Institute 
[ADDRESS_96652]. 
Durham, NC [ZIP_CODE] 
Phone: 919-6 84-2584 
Email: susanna.naggie@duk e.edu  
Chris Lind sell, PhD 
Vanderbilt University School of Medicine 
[ADDRESS_96653], Rm [ZIP_CODE] 
Nash ville, TN  [ZIP_CODE] 
Phone: 615-3 43-9867 
Email: [EMAIL_1777] 
National Center f or Advancing Translational Sciences 
2.0 
025MAY 2021 [STUDY_ID_REMOVED]
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 2 Statement of Compliance  
 
This trial will be conducted in compliance with the International Council for Harmonisation 
(ICH) E6 (R2) guideline for Good Clinical Practice (GCP), and the applicable regulatory 
requirements from the [LOCATION_002] (US) Code of Federal Regulations (CFR), including 45 CFR 
46 (Human Subjects Protection); 21 CFR 312 (Investigational New Drug); 21 CFR 50  (Informed 
Consent), and 21 CFR 56 (Institutional Review Board).  
All individuals who are responsible for the conduct, management, or oversight of this study ha ve 
completed Human Subjects Protection and ICH GCP Training.  
 
 
  
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 [ADDRESS_96654] read the protocol, including all appendices, and the package insert (s)/product label (s), and 
I agree that the protocol contains all necessary details for my staff and me to conduct this study 
as described. I will personally oversee the conduct of this study as outlined herein and will make 
a reasonable effort to complete the study within the time designated. I agree to make all reasonable effort s to adhere to the attached protocol.  
I will provide all study personnel under my supervision with copi[INVESTIGATOR_88472]‚Äôs representative.  I will discuss this 
material with study personnel to ensure that they are fully informed about the efficacy and safety 
parameters and the conduct of the study in general. I am aware that, before beginning this study, 
the IRB, or equivalent oversite entity must approve this protocol in the clinical faci lity where it 
will be conducted.  
I agree to obtain informed consent from participants, as required by [CONTACT_88526] I CH guidelines. I further agree to report to the sponsor 
or its representative any adverse events in accordance with the t erms of this protocol and the U S 
CFR, Title 21, part 312.64, ICH GCP 4.11. I further agree to ensure the study is conducted in 
accordance with the provisions as stated and will comply with the prevailing local laws and 
customs . 
  
   
Site Principal Investigator [CONTACT_5627] (Print)   
   
   
Site Principal Investigator [INVESTIGATOR_88473] -6 Protocol [v2.0] 
 
 4 Table of Contents  
1. Protocol Summary.................................................................................................  12 
1.1. Synopsis  .................................................................................................................. 12 
1.2. Schema .................................................................................................................... 18 
2. Introduction  .......................................................................................................... 19 
2.1. Study Rationale  ........................................................................................................ 19 
2.2. Background .............................................................................................................. 19 
2.3. Benefit/Risk Assessment  .......................................................................................... 20 
2.3.1.  Risk Assessment ....................................................................................................... 20 
2.3.2.  Benefit Assessment  .................................................................................................. 20 
3. Objectives and Endpoints ...................................................................................... 21 
4. Study Design.......................................................................................................... 23 
4.1. Overall Design  ......................................................................................................... 23 
4.2. End of Study Definition ............................................................................................ 23 
5. Study Population  ................................................................................................... 24 
5.1. Inclus ion Cr iter ia ...................................................................................................... 24 
5.2. Exclu s ion Cr iter ia  .................................................................................................... 24 
5.3. Recruitment and Engagement  ................................................................................... 24 
5.3.1.  Participant Recruitment  ............................................................................................ 24 
5.3.2.  Participant Engagement  ............................................................................................ 24 
5.3.3. Participant Randomization Process ............................................................................ 25 
5.4. Screen Failures ......................................................................................................... 25 
5.5. Enrollment  ............................................................................................................... 25 
6. Study Drug(s)  ........................................................................................................ 26 
6.1. Repurposed Medication Treatments  .......................................................................... 26 
6.2. Placebo  .................................................................................................................... 26 
6.3. Study Drug Accountability  ....................................................................................... 26 
6.4. Concomitant Therapy  ............................................................................................... 26 
6.5. Intervention After the End of the Study  ..................................................................... 26 
7. Participant Withdrawal/Termination and Study Termination ............................. 27 
7.1. Participant Withdrawal/Termination  ......................................................................... [ADDRESS_96655] to Follow -up ..................................................................................................... 27 
8. Study A ssessments and Procedures ....................................................................... 29 
8.1. Schedule of Events  ................................................................................................... 30 
8.1.1.  Screening  ................................................................................................................. 31 
8.1.2.  Intervention Period  ................................................................................................... 31 
8.1.3.  Follow -up Period  ...................................................................................................... 32 
8.1.4.  Fina l V is it  ................................................................................................................ 32 
8.2. Clinical Assessments  ................................................................................................ 33 
8.3. Quality of Life Questionnaires  .................................................................................. 34 
9. Safety Assessments ................................................................................................ 35 
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 [ADDRESS_96656] (ADE) and Unanticipated Adverse 
Device Effect (UADE) .............................................................................................. [ADDRESS_96657] .......................................................................................... 38 
9.2. Unanticipated Problem (UP) and Terminations .......................................................... 39 
9.2.1.  Definition of Unanticipated Problem  ......................................................................... 39 
9.2.2.  Reporting of an Unanticipated Problem  ..................................................................... 39 
10. Statistical Considerations  ...................................................................................... 40 
10.1.  Statistical Hypotheses ............................................................................................... 40 
10.1.1.  Primary Hypothesis  .................................................................................................. 40 
10.2.  Sample Size Determination ....................................................................................... 40 
10.3.  Randomization  ......................................................................................................... 40 
10.4.  Blinding ................................................................................................................... 40 
10.5.  Populations for Analyses  .......................................................................................... 41 
10.6.  Statistical Analyses  .................................................................................................. 41 
10.6.1.  General Considerations  ............................................................................................. 41 
10.6.2.  Statistical modeling  .................................................................................................. 42 
10.6.3.  Model priors ............................................................................................................. 43 
10.6.4.  Assessing Effectiveness  ............................................................................................ 44 
10.6.5.  Planned Interim Analyses, Early Stoppi[INVESTIGATOR_007], and Type -I Error 
Control ..................................................................................................................... 44 
10.6.6.  Sensitivity and Supplementary Analyses  ................................................................... 45 
10.6.7.  Differential Treatment Effects and Subgroup Analyses  .............................................. 46 
10.6.8.  Secondary Clinical Endpoint  ..................................................................................... 46 
10.6.9.  Exploratory Analysis  ................................................................................................ 46 
10.6.10.  Adherence and Retention Analysis  ............................................................................ 47 
10.7.  Interim Reporting  ..................................................................................................... 47 
10.8.  Independent Data Monitoring Committee (IDMC)  .................................................... [ADDRESS_96658] (IRB) .............................................................................. [ADDRESS_96659] Keepi[INVESTIGATOR_007]  ..................................................................... 51 
12.1.  Data Collection and Management Responsibilities  .................................................... 51 
12.2.  Study Records Retent ion .......................................................................................... 51 
12.3.  Protocol Deviat ions  .................................................................................................. 51 
12.4.  Publication and Data Sharing Policy  ......................................................................... 51 
13. Study Leadership .................................................................................................. 53 
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 6 14. Summary of Changes  ............................................................................................ 54 
15. R ef er enc es  ............................................................................................................. 56 
16. Appendix A ‚Äì Ivermectin  ...................................................................................... [ADDRESS_96660]  ......................................................................................... 65 
17. Appendix B ‚Äì Fluvoxamine maleate  ...................................................................... [ADDRESS_96661]  ......................................................................................... 71 
18. Appendix C ‚Äì Arnuity Ellipta (fluticasone furoate inhalation 
powder) .................................................................................................................. 72 
18.1.  Risk Assessment  ...................................................................................................... 72 
18.2.  Addit i onal Appendix-Leve l E xclus ion Cr iter ia  .......................................................... 73 
18.2.1.  Precautions ............................................................................................................... 73 
18.3.  Arnuity Ellipta Information  ...................................................................................... 74 
18.3.1.  Formulation, Appearance, Packaging, and Labeling  ................................................... 74 
18.3.2.  Drug Dispensing, Storage, and Stability  .................................................................... 74 
18.3.3.  Dosing and Administration  ....................................................................................... 74 
18.3.4.  Rationale for Selection of Dose  ................................................................................. 74 
18.4.  Placebo Information  .................................................................................................  75 
18.4.1.  Formulation, Appearance, Packaging, and Labeling  ................................................... 75 
18.4.2.  Drug Dispensing, Storage, and Stability  .................................................................... 76 
18.4.3.  Dosing and Administration  ....................................................................................... 76 
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 [ADDRESS_96662]  ......................................................................................... 76 
18.6.  Safety Reporting for Arnuity Ellipta .......................................................................... 76 
 
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 [ADDRESS_96663]  
KO Knockout  
LPS Lipopolysaccharide  
MAOI  Monoamine Oxidase Inhibitors  
mITT  Modified Intention to Treat  
MOP  Manual of Procedures  
NCATS  National Center for Advancing Translational Sciences  
NIH National Institute  of Health  
OCD  Obsessive Compulsive Disorder  
OHRP  Office for Human Research Protections  
OR Odds Ratio  
PCORI  Patient -Centered Outcomes Research Institute  
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 9 PCR  Polymerase Chain Reaction  
PHI Personal Health Information  
PHQ  Patient Health Questionnaire  
PPOS  Predicted Probability of S uccess  
PROMIS  Patient -reported Outcomes Measurement Information System  
QOL Quality of Life  
RRT  Renal Replacement Therapy  
SAE Serious Adverse Event  
SAP Statistical Analysis Plan  
SARS -CoV-1/2 Severe Acute Respi[INVESTIGATOR_696] S yndrome Coronavirus 1/[ADDRESS_96664]  
UP Unanticipated Problems  
US [LOCATION_002]  
WT Wildtype  
  
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 10 Table of Figures  
Figure 1: ACTIV -6 Study Schema  ..........................................................................................18  
Figure 2: Operational Structure Diagram  .................................................................................53  
Figure 3: Survival curve of WT and S1R KO mice  ..................................................................69  
Figure 4:  Summary of JAMA Randomization Clinical Trial of Fluvoxamine for Early COVID -
19. .........................................................................................................................................70  
Figure 5:  Summary of study results for the prospective, nonrandomized observational cohort 
study with fluvoxamine in participants diagnosed with COVID -19...........................................71  
 
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 [ADDRESS_96665] of Tables  
Table 1: Schedule of Events  ....................................................................................................30  
Table 2: ACTIV -6 Sample Size Estimates and Power  ..............................................................40  
Table 3: Ivermectin Adverse Event Table for Doses ‚â•  300 ¬µg/kg .............................................61  
Table 4: Ivermectin Dosing Schedule  ......................................................................................63  
Table 5. Fluvoxamine Adverse events occurring in 10-week studies of adult OCD or depression
 ..............................................................................................................................................66  
Table 6. Fluvoxamine Adverse events that occurred in COVID -19 study participants receiving 
300 mg/day for 15 days. ..........................................................................................................67  
Table 7. Fluticasone Adverse reactions that occurr ed in ‚â•3% of adults and adolescents with 
asthma in a 24-week tr ia l.  .......................................................................................................72  
 
 
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 12 1. Protocol Summary 
1.1. Synopsis  
 
Title ACTIV -6: COVID -19 Outpatient Randomized Trial to Evaluate 
Efficacy of Repurposed Medications  
Clinical study phase  III 
Rationale  Coronavirus Disease 2019 ( COVID -19) is caused by a novel 
coronavirus, severe acute respi[INVESTIGATOR_6507] 2 
(SARS -CoV -2), that first emerged  in December  [ADDRESS_96666] received emergency use authorizatio n. However, 
the pandemic continues to evolve with new variants and surges of infections in different regions of the world , requiri ng an ongoing 
evidence -generating clinical trial platform, in particular for the 
treatment of COVID -19 in the outpatient setti ng. This platform 
protocol can serve as an evidence generation system for prioritized 
drugs , repurposed from other  Food and Drug Administration ( FDA ) 
indications with an established safety record in humans  and 
preliminary data of efficacy.  The ultimate goa l is to evaluate if 
repurposed medications can make participants feel better faster and 
reduce death and hospi[INVESTIGATOR_059].  
Primary Objective  ‚Ä¢ To evaluate the effectiveness  of repurposed medications  [(study 
drug(s)]  in reducing symptoms of nonhospi[INVESTIGATOR_88474] -19 
Secondary 
Objectives  ‚Ä¢ To evaluate the clinical outcomes  (e.g. hospi[INVESTIGATOR_88475]) in participants in a study drug arm versus those in the 
placebo arm  
‚Ä¢ To describe symptom resolution in participants in a study drug 
arm versus those in the placebo arm  
‚Ä¢ To describe the quality of life (QOL) in participants in a study 
drug arm versus those in the placebo arm  
Exploratory Objectives  ‚Ä¢ To describe long-term COVID -19-related symptoms in 
participants in a study drug arm versus those in the placebo 
arm  
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 [ADDRESS_96667] of care. Each 
study drug appendix describes a different study drug and 
matching placebo. The following arms will be included in each 
study appendix:  
‚Ä¢ Study Drug Arm: repurposed medications (see 
Appendices)  
‚Ä¢ Placebo  Arm: placebo  control  
While each appendix describes  the placebo that matches the 
study drug, for comparative analysis the control group will 
comprise  eligible , concurrent ly enrolled participants from all 
placebo arms .  
Study Design This study is a platform  protocol designed to be flexible so that 
it is suitable for a wide range of settings within healthcare 
systems and in community settings where it can be integrated 
into routine COV ID-19 testing programs and subsequent 
treatment plans. Th is platform  protocol will enroll participants in 
an outpatient setting with a confirmed polymerase chain reaction 
(PCR) or antigen test for SARS -CoV -2. Each appendix will 
describe a repurposed medica tion ( study drug) to meet the 
protocol objectives.  
When only one study drug/appendix is under study, allocation 
between study drug and placebo will be 1:1. If multiple study 
drugs/appendices  are under study, participants will  also be 
randomized among the study drugs  for which eligibilit y is 
confirmed. Since the route of administration of each study drug may differ, the placebos may also differ. To achieve blinding 
and an equitable randomization probability, a  two step 
randomization process will be used.  
In the first step, the participant will be  randomized m:1 active  
study drug to placebo, where m is the number of active study 
drugs  for which the participant is eligible.  Then, participants  will 
be randomized among the  m study drugs  for which they are 
eligib le. Participants wi ll carry their ‚Äòstudy drug‚Äô versus 
‚Äòplacebo‚Äô randomization with them into the study drug appendix. 
In this way, a participant  allocated to placebo who is randomized 
to study drug A will be given the placebo that matches s tudy 
drug A. This achieves equal probability of exposure to a placebo 
or an active  study drug, and equitable distribution among all 
study arms for which a participant is eligible.  Sites will be 
informed to which study drug appendix the participant is  
randomized, but not whether they are allocated to the study drug 
arm or placebo arm within that appendix.  
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 14 For analysis, concurrent placebo participants who were eligible 
for the study drug appendix will be pooled. This will result in 
approximately a 1:[ADDRESS_96668] udy drugs.   
Participants will receive complete supply of repurposed 
medication (study drug) or placebo with length of treatment and 
amount of study drug/placebo depending on the  study drug 
appendix and arm  to which they are randomize d. 
This study is designed so that it can be done completely 
remote ly. However, screening and enrollment may occur in 
person at sites and unplanned s tudy visit s may occur in-person 
or remotely, as deemed appropriate by [CONTACT_88527] . Participants will be on-study for 90 days, during which 
they will complete various questionnaires.  
Population Up to 15,000 adults   
Study Duration 24 months  
Study Location Up to 280 sites   
Inclusion Criteria  1. Completed Informed Consent  
2. Age ‚â•[ADDRESS_96669] collected within 10 days of 
screening  
4. Two or more c urrent symptoms of acute infection for ‚â§ 7 days. 
Symptoms include the following:  fatigue, dyspnea, fever, cough, 
nausea, vomi ting, diarrhea, body aches , chills, headache, sore 
throat, nasal symptoms, new loss of sense of taste or smell  
Exclusion Criteria  1. Prior diagnosis of COVID -19 infection (> 10 days from 
screening)  
2. Current or recent (within 10 days of screening) hospi[INVESTIGATOR_3094]  
3. Current use of study drug or study drug/device combination*  
4. Known allergy/sensitivity or any hypersensitivity to 
compone nts of the study drug or placebo*  
5. Known contraindication to study drug including prohibited 
concomitant medications (see Appendices) * 
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 15 *If only one study drug  appendix  is open at the time of enrollment. 
If multiple study drug appendices  are open, a participant may opt -
out of any study drug  appendix or be excluded from a ny study drug  
appendix based on contraindications listed in the s tudy drug 
appendix , current use of study drug,  or known 
allergy/sensitivity/hypersensitivity  and still remain eligible for the 
remaining study drug appendi ces. 
Sample S ize 
Considerations  An estimated sample size of ~ [ADDRESS_96670] >85% power to determine whether 
there is evidence of meaningful benefit . This will involve [ADDRESS_96671] of each study drug versus matching placebo will 
be quantified using the common odds ratio ( OR) from the 
proportional odds model (primary estimand). Evidence for efficacy 
will be quantified as the posterior probability that the OR is less 
than 0.9. This is denoted as the ‚Äúposterior probability for efficacy‚Äù 
or ùëÉùëÉ(ùëÇùëÇùëÇùëÇ<0.9|Data ). Similarly, the risk difference in 
hospi[INVESTIGATOR_88476]. Regardless of whether there is an efficacy signal, 
the following quantities from the model  will be reported : 
‚Ä¢ Mean and median time to symptom freedom (for quantifying 
benefit on symptoms)  
‚Ä¢ Mean and median time to hospi[INVESTIGATOR_30059] (secondary 
outcomes)  
The primary analysis will be implemented separately for each study 
drug, where the matching placebo arm will consist of concurrently 
randomized participants that meet the inclusion and exclusi on 
criteria for that study drug appendix. A modified intention to treat  
(mITT) approach will be used for primary analyses ; all participant s 
who receive study drug will be included as assigned. It is possible  
that the delivery of medications (placebo or study drug ) does not 
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 16 occur; this will result in exclusion of the participant for the mITT 
analysis. All available data will be used to compare each study drug 
versus placebo control, regardless of post -randomization adherence 
to study protocols.  
Independent Data 
Monitoring 
Committee (IDMC )  Frequent IDMC  reviews will be conducted to ensure the safety of 
study participants and evaluate the accumulating endpoint data by [CONTACT_1570]. Regular IDMC  meetings will monitor the 
following parameters at a minimum:  
‚Ä¢ Recruitment progress  
‚Ä¢ Enrollment overall and by [CONTACT_12125]  
‚Ä¢ Adherence, retention, and status of data collection 
‚Ä¢ Serious adverse events  
‚Ä¢ Assessment for futility  
‚Ä¢ Probability for benefit across endpoints  
Interim Analysis  Interim analyses will be performed per s tudy drug appendix , after 
approximately every 200 participants  (100 in study drug arm and 
100 in placebo arm)  have completed the Day  [ADDRESS_96672] regardless of 
final study drug arm allocation . The following decision thresholds 
will be checked at each interim  analysis : 
i) The study drug is found to have benefit (efficac y): A 
posterior probability of meaningful benefit  (e.g. OR < 
0.9) for a  study drug in comparison to the placebo 
control of > 0.95 will result in a declaration of  overall  
superiority.   
a. If a study drug arm is declared superior, a futility 
analysis will be conducted on observing clinical 
efficacy (reduction in hospi[INVESTIGATOR_88477]) if the 
study drug arm were to continue for an additional 
one year . Accrual will be projected based on actual 
trial accrual and projected case rates. Stoppi[INVESTIGATOR_88478] (PPOS) is  low (e.g.  <0.1) and 
will be discouraged if the PPOS is  high (e.g.  >0.7).   
ii) The study drug is found to be substantially similar t o the 
placebo control  (inefficacy ): A posterior probability of 
>0.95 that there is  no more than trivial benefit (e.g. OR 
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 17 > 0.9) or harm of an arm will result in termination of 
that arm.   
iii) The study drug is found to cause harm (inferiority) : A 
posterior probability of >0.85 for worse adverse clinical 
outcomes (hospi[INVESTIGATOR_30059]) for a  study drug 
relative to the placebo control  (e.g. a risk difference > 
0.01) will result in termination of that arm.  
iv) The predicted probability of success of any study drug 
given expected accrual at a prespecified point in time will be provided to the IDMC . Stoppi[INVESTIGATOR_88479] (e.g. <0. 1) 
and will be discouraged if the PPOS  is high (e.g. >0.7).  
Note that unlike the probability of inefficacy, PPOS involves Bayesian posterior predictive distributions.  
Futility is a low probability of achieving any conclusions within a 
reasonable time frame or with available resources . Prior t o each 
interim analysis, the target date for study completion will be specified, and accrual will be projected by [CONTACT_88528]. A 
statistical model may be used to predict accrual.  
Futility assessment 
will use the lowest of either the planned accrual or  predicted 
accrual at study closure.  
The combination of decision thresholds and effect sizes have been 
selected to balance the ability to observe a meaningful effect on 
symptoms, to observe the potential for an effect on clinical 
outcomes, and to maximize power. In making decisions, power will 
be balanced with the  Type [ADDRESS_96673] 
5%. 
 
 
 
 
  
 
  
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 18 1.2. Schema  
 
 
Figure 1: ACTIV -6 Study Schema  

CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 19 2. Introduction 
2.1. Study Rationale  
Severe acute respi[INVESTIGATOR_6507] 2 (SARS -CoV -2) is a novel betacoronavirus  that 
first emerged in December [ADDRESS_96674] to the number of cases and overall mortality. [1, 2]  The clinical disease 
related to  SARS-CoV -2 is referred to as Coronavirus Disease 2019 ( COVID -19). Over 2020, 
advances were made for treatment of COVID -[ADDRESS_96675] received 
emergency use authorization for prevention of SARS -CoV -2 infections.  [3-8] However, the 
pandemic continues to evolve with new variants and surges of infections in different regions of 
the world , requiring an ongoing evidence -gener ating platform, in particular for the  treatment of 
COVID -[ADDRESS_96676] and preliminary evidence of clinical efficacy for the treatment of COVID -19. The 
ultimate goal is to evaluate if repurposed medications can make participants feel better faster and 
reduce death and hospi[INVESTIGATOR_059].  
2.2. Background 
In December  2019,  numerous patients in Wuhan, China were diagnosed with pneumonia caused 
by [CONTACT_88529]. By [CONTACT_36466] 7 , 2020,  Chinese scientists had isolated SARS -CoV -2. This is 
a nove l betacoronavirus closely related to severe acute respi[INVESTIGATOR_6507]  1 
(SARS -CoV -1). [2]  In the subsequent months the spread of the virus led to  a global pandemic. 
As of February 10,  2021 there were approximately 107,002,486 confirmed COVID -19 cases 
resulting in  2,343,477 deaths worldwide. [1] 
The virus continues to spread despi[INVESTIGATOR_88480]. COVID -
19 vaccinations are actively being distributed and administered  in some countries ; however, new 
SARS-CoV -2 strains continue to emerge, with early reports of potential for  reduced  monoclonal 
antibody therapeutic and  vaccine efficacy.  [9] Additionally, data regarding transmission  after 
vaccination is pending, highlighting the need to establish treatment regimens despi[INVESTIGATOR_88481]. Finally, while vaccine roll-out is occurring, sufficient  immune  coverage to reach 
herd immunity across the globe is unlikely in the next year. Thus, there remains a need to 
identify safe and efficacious  treatments that can be administered in the outpatient  setting.  
As of February 2021,  multiple clinical trials have been reporte d, providing early guidance to 
clinical providers on management of COVID -19, particularly in the hospi[INVESTIGATOR_6885]. One drug 
has been approved by [CONTACT_88530] (remdesivir) and one has been 
FDA approved for years (dexamethasone) ; both have been reported to improve clinical disease 
and in the case of dexamethasone, mortality . [10, 11]  Numerous medications are currently under 
investigation including monoclonal antibodies to spi[INVESTIGATOR_88482] , including tocilizumab . No therapi[INVESTIGATOR_88483] - or 
post-exposure prophylaxis  nor for therapy of outpatients, although there are several 
investigational agents authori zed for emergency use  by [CONTACT_1622], including bamlanivimab, 
bamlanivimab + etesevimab  in combination, and casirivimab + imdevimab in combination. [12, 
13]   
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 20 2.3. Benefit/Risk Assessment  
The risks for participation in this study include  taking study drug (see Appendices)  and loss of 
confidentiality.  There may be some benefit to the participant if the therapy is effective against 
COVID -19. 
2.3.1.  Risk Assessment  
Loss of confidentiality risks: There is a potential risk of loss of confidentiality. Every effort will 
be made to protect the participant‚Äôs confidential medical information, but this cannot be 
guaranteed. Clinical information will not be released without written permission of the  
partic ipant, except as necessary for monitoring by [CONTACT_1201], FDA, National Institutes of Health 
(NIH), Office for Human Research Protections (OHRP ), other local, US, and international 
regulatory authorities/entities as part of their duties.  
Risk lowering measures: Study procedures to manage and minimize risks include careful 
selection of the participants and monitoring over time to check on participants ‚Äô health. 
Additional guidance to manage any risks  or any change to the risk to the participant  based on 
emerging data will be provided to the study teams, as needed. In addition, an independent 
Independent Data Monitoring Committee  (IDMC ) will monitor safety of the participants 
throughout the study.  
2.3.2.  Benefit Assessment  
Participants who randomize to a study drug arm may benefit from study drug administration.  
There is no direct benefit to participants randomized to the placebo arm  apart from participating 
in generating evidence that may ultimately support treatment  for SARS -CoV -2 infection. In 
addition, they will be nefit from involvement with the team following their health status during 
the study. The knowledge gained will be a benefit to others in the future.  
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 21 3. Objectives and Endpoints  
Objectives  Outcome Measurement s Reported Endpoint s 
Primary    
To evaluate the 
effectiveness of repurposed 
medications  [(study drug(s)] 
in reducing symptoms in 
nonhospi[INVESTIGATOR_88484] -19 The following will be evaluated 
from baseline through Day 14:  
‚Ä¢ Hospi[INVESTIGATOR_3094]  
‚Ä¢ Death  
‚Ä¢ Symptom count  The following model -
assisted endpoints will be 
reported for the primary 
objective:  
‚Ä¢ The odds ratio ( OR) 
describing the overall 
difference  in symptoms and 
clinical events over the 14 
days 
‚Ä¢ The overall risk difference 
for hospi[INVESTIGATOR_88475]  
‚Ä¢ Mean and median time to 
symptom freedom  
Secondary   
To evaluate the clinical 
outcomes  (e.g. 
hospi[INVESTIGATOR_9017]) in 
participants in a study drug 
arm versus those in the 
placebo arm  ‚Ä¢ COVID Clinical Progression  
Scale on Day 7, Day 14, and 
Day 28 (see Section 8.2) 
‚Ä¢ Hospi[INVESTIGATOR_88485] 28 
‚Ä¢ Mortality through Day 28 
‚Ä¢ Hospi[INVESTIGATOR_3094], urgent care 
visit, emergency room visit 
through Day 28 The following model -
assisted endpoints will be 
reported for the COVID Clinical Progression Scale : 
‚Ä¢ The OR describing the 
overall difference in 
clinical progression  
‚Ä¢ The OR describing the 
difference in clinical 
progress ion at each 
measured time point  
‚Ä¢ The overall risk difference for hospi[INVESTIGATOR_88486]:  
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 22 ‚Ä¢ The overall risk difference 
for any of urgent care, 
emergency care, 
hospi[INVESTIGATOR_88487] 
‚Ä¢ Time to first urgent care, 
emergency care, 
hospi[INVESTIGATOR_30059]  
‚Ä¢ Risk and time to event for each component of the 
composite  
To describe symptom 
resolution in participants in 
a study drug arm versus 
those in the placebo arm  Symptom resolution, defined as 
first of at least three co nsecutive 
days without symptoms  Directly measured mean and 
median t ime to symptom 
resolution 
To describe the quality of 
life (QOL) in participants in 
a study drug arm versus 
those in the placebo arm  Modified Patient -Reported 
Outcomes Measurement 
Information System (PROMIS)-
29 at baseline, Day 7, Day 14, 
Day 28, and Day 90 Follow -up Model -assisted endpoints 
will be reported for QOL 
scores:  
‚Ä¢ Overall OR  
‚Ä¢ Odds ratios ( ORs) specific 
to days 7, 14, 28 and 90 
‚Ä¢ Mean difference in QOL 
scores at each time point  
Exploratory   
To describe long -term 
COVID -19-related 
symptoms in participants in 
a study drug arm versus 
those in the placebo arm  Symptom occurrence, type, and 
severity at Day 90 Follow -up 
 Directly measured m ean and 
median symptom count and 
QOL score at Day 90 in 
study drug arm(s) versus 
placebo.  
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 [ADDRESS_96677]  for SARS -CoV -2 infection . Each appendix will describe a repurposed 
medication ( study drug arm) that is sized to meet the master protocol  objectives.  
Participants will be randomized based on the study drug appendices  that are actively enrolling at 
the time of randomization. Study drug appendices  may be added or removed according to 
adaptive design and/or  emerging evidence. When there  are mu ltiple study drug a ppendices  
available, randomization will occur based on appropriateness of each drug for the participant  as 
determined by [CONTACT_88531] . Each participant 
will be required to randomize to at least one study drug versus placebo.  The probability of 
placebo to treatment will remain the same regardless of eligibil ity  decisions.   
Eligible participants will be randomized (1:1), in a blinded fashion, to either the study drug 
arm or placebo arm  in addition to standard of care . As additional study drug appendices  are 
added, the randomization will be altered to leverage placebo data across arms. Participants 
will receive a complete supply of repurposed medication (study drug) or placebo with the 
quantity depending on the study drug/placebo to which they are randomize d. 
All study visits are designed to be remote. However, screening and enrollment may occur in-
person at sites and unplanned study visit s may occur in-person or remotely, as deemed 
appropriate by [CONTACT_88532] . Participants will be asked to complete 
questionnaires and report  safety events  during the study, according to Table 1. Participants will 
be prompted by [CONTACT_88533], as necessary .  
4.2. End of Study  Definition  
A participant is considered to have completed the study if he/she has completed the Long-term 
Follow -up assessments at [ADDRESS_96678] participant in the 
study. Data from interim analyses or recommendations  by [CONTACT_88534].   
 
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 24 5. Study Population 
All Eligibilit y Criteria will be obtained per participant.   
5.1. Inclusion Criteria  
1. Completed Informed Consent  
2. Age ‚â• 30 years old 
3.   Confirmed SARS -CoV -2 infection by [CONTACT_88535] ( PCR) or antigen test collected within 10 days of s creening  
4. Two or more c urrent symptoms of acute infection for ‚â§ 7 days. Symptoms include the 
following: fatigue, dyspnea, fever, cough, nausea, vomiting, diarrhea, body aches , chills, 
headache, sore throat, nasal symptoms, new loss of sense of taste or smell  
5.2. Exclusion Criteria   
1. Prior diagnos is of COVID -19 infection (> 10 days from screening)  
2. Current or recent (within 10 days of screening) hospi[INVESTIGATOR_3094]  
3. Current use of study drug or study drug/device combination *  
4. Known allergy/sensitivity or any hypersensitivity to components of the study drug or 
placebo * 
5. Known contraindication(s) to study drug including prohibited concomitant medications 
(see Appendices) * 
*If only one study drug appendix is open at the time of enrollment. If multiple study drug appendices are open, a participant may opt -out of any study drug appendix or be 
excluded from any study drug appendix based on contraindications listed in the study 
drug appendix , current use  of study drug , or known allergy/sensitivity/hypersensitivity 
and still remain eligible for the remaining study drug appendices.  
5.3. Recruitment and Engagement  
5.3.1.  Participan t Recruitment  
Participants who are eligible based on positive SARS -CoV -[ADDRESS_96679] will be 
identified by [CONTACT_88536] -identify to a central study hotline (s) and be referred to 
the closest site . Site investigators, or their des ignee, may contact [CONTACT_88537].  
5.3.2.  Participant Engagement  
Participants will be engaged in the study through multiple channels. This includes , but is not 
limited to , ongoing participation in other registries partnering with ACTIV or healthcare systems.  
Additionally, participant engagement will include:  
‚Ä¢ compensation for participants who complete the Day 90 Final Visit;  
‚Ä¢ creating a study-wide ACTIV -6 Advisory Group;  
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 25 ‚Ä¢ developi[INVESTIGATOR_88488] -centered approaches that recognize the needs and preferences of 
COVID -19 survivors locally and nationally; and 
‚Ä¢ multifaceted approaches that combine engagement tool s, leverage the online system , use 
of social media , and representative  COVID -Participants . 
5.3.3.  Participant Randomization  Proce ss  
This trial is a double -blind, placebo-controlled trial. Pa rticipants and investigators will be  
blinded. A participant who is eligible for m  study drug arms /appendices  will be randomized m:1 
study drug to placebo ( Figure 1). The participant will then be randomized with 1/ m probability to 
each of the study drug appendices . A participant entering a study drug appendix carries their 
study drug or placebo designation with them and will get either the study drug or matching 
placebo. Participants who receive placebo will be pooled across study drug arms for those study 
drug arms /appendices  that the participant is eligible. This reduces overall sample size by 
[CONTACT_88538] a 1:1 allocation to study 
drug or placebo.  Randomization sequences will not be pre -generated. Given the adaptive nature  
of the trial and the unknown number of study drug appendice s, arm assignment will be 
implemented at the time of confirming eligibility for randomization using a random number 
generator. The participant eligibility criteria will be checked for each study  drug appendix, and 
the randomization probabilities will be set. The two step procedure will then occur, and the 
assignment to both s tudy drug appendix and study drug versus placebo will be made. The 
participant and study teams will know w hich study drug appendix the participant is allocated to , 
but will be blinded to study drug versus placebo because they will be matching.  
The participant, treating clinicians, and study personnel will remain blinded to study drug versus 
placebo  assignment until after the da tabase is locked and blinded analysis is completed. Only the 
biostatistical team who is preparing closed IDMC  interim reports will be unblinded. Specifically, 
study drug/placebo will be dispensed with packaging and labelling that would blind treatment 
assignment. Unblinding will occur only if required for participant  safety or treatment at the 
request of the treating clinician.  Refer to the Manual of Procedures (MOP) for further details.  
5.4. Screen Failures  
Screen failures are defined as participant s who consent to participate in the clinical study, who 
fulfill inclusion and exclusion criteria,  but are not subsequently randomized. A minimal set of 
screen failure information is required to ensure transparent reporting of screen failure 
participant s to meet the Consolidated Standards of Reporting Trials (CONSORT) publishing 
requirements and to respond to queries from regulatory authorities.   
Individuals who are considered screen failures  may not be re -screened.  
5.5. Enrollment  
Participants who are randomized and receive study drug/placebo will be considered enrolled. Participants who are randomized, but do not receive study drug/placebo for any reason (e.g. 
study drug lost in the mail), will not be considered enrolled on the study and will be identified as 
consented not enrolled.  
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 26 6. Study Drug (s) 
6.1. Repurposed Medication Treatments  
See Appendices  
6.2. Placebo  
See Appendices  
6.3. Study Drug Accountability  
Use of study drug will be tracke d via the online system , call center , or sites . Participants will 
dispose of any unused study drug as they would normally when stoppi[INVESTIGATOR_007] a medication.  
6.4. Concomitant Therapy  
Select concomitant medications of interest  that the participant is receiving at the time of 
enrollment or receives during the course of the study will be recorded along with dosing 
information. Select concomitant medications of interest include the following and will be 
verified at each remote visit by [CONTACT_51015] : 
‚Ä¢ Any t herapeutics that is thought to have potential  or purported COVID activity  including 
hydroxychloroquine   
‚Ä¢ Antibiotics  
‚Ä¢ Antifungals  
‚Ä¢ Antiparasitic  
‚Ä¢ Antivirals including HIV protease inhibitors and ribavirin 
‚Ä¢ Immunosuppressants including s teroids  
‚Ä¢ Angiotensin-converting-enzyme ( ACE )/angiotensin II receptor  blockers 
(ARB)/ angiotensin receptor neprilysin inhibitor ( ARNI ) 
‚Ä¢ Statin 
‚Ä¢ Anticoagulants and antiplatelets  
‚Ä¢ COVID -19 vaccine (before, during, or after study intervention)  
Refer to the MOP for more details on concomitant therapy. Refer to the appendices for 
contraindicated  medications for each of the study drugs.  
6.5. Intervention Afte r the End of the Study  
No additional study drug will be provided to the participant following completion of the study.   
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 27 7. Participant Withdrawal /Termination and Study Termination 
7.1. Participant Withdrawal/Termination  
Participants will be followed until participant closeout, withdrawal of consent, or death.  
A participant may withdraw from the study at any time at his/her own request, or may be 
withdrawn at any time at the discretion of  the investigator for safety, behavioral, compliance, or 
administrative reasons. This is expected to be uncommon.  
Those who request withdraw al from the study will be asked to continue on study follow -up with 
limited participation through the Final Visit ( Section 8.1.4).  Limited participation may include a 
call(s) to assess safety  at study visits following withdrawal . 
If the participant withdraws consent for disclosure of future information, the sponsor may retain 
and continue to use any data collected befor e such a withdrawal of consent.  
7.2. Premature Termination or Suspension of the Study  
The study may be temporarily suspended  or prematurely terminat ed if there is sufficient 
reasonable cause. Written notification will be provided documenting reason for study suspension 
or termination to the investigators, funding agency, and regulatory authorities , as appropriate . 
Circumstances that may warrant termin ation or suspension include, but are not limited to:  
‚Ä¢ Determination of unexpected, significant, or unacceptable risk to participants  
‚Ä¢ Insufficient compliance to protocol requirements  
‚Ä¢ Data that are not sufficiently complete and/or evaluable  
‚Ä¢ Determination of futility after a sufficient time has passed for accrual of the primary and 
secondary outcomes  
‚Ä¢ Recommendation by [CONTACT_31849]  
7.3. Lost to Follow -up 
Participants will be asked for proxy contacts to assess vital status and/or other clinical events , 
including safety,  if a participant fails to provide the information. Provision of proxy information 
is not required for study participation. A participant  will be considered lost to follow -up if he or 
she repeatedly fails to  complete study assessments/procedures  as outline d below  and neither the 
participant nor the participant‚Äôs  proxy can be contact[CONTACT_9298].  
The following actions must be taken if  a participant  fails to provide baseline  information, if they 
fail to complete daily symptom reporting by [CONTACT_88539]/placebo  (Day 2) , if they miss two consecutive daily symptom reportings  during Days 
3 to 14,  if they miss either the Day 14 or Day 28 Remote Visits, and/or they fail to complete the 
Day 90 assessments:  
‚Ä¢ The site or call center  must attempt to contact [CONTACT_88540]/procedures . 
‚Ä¢ The site or call center will contact [CONTACT_2299]‚Äôs proxy to assess vital status and/or 
other clinical or safety events.  
‚Ä¢ The site or call center will attempt to collect all missing survey responses . 
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 28 ‚Ä¢ Before a  participant  is deemed lost to f ollow -up, the investigator or designee must make 
every effort to regain contact [CONTACT_6635]  (where possible, three telephone calls 
and, if necessary , a certified letter to the participant ‚Äôs last known mailing address or 
local equivalent methods). These contact [CONTACT_21457] ‚Äôs research  record . 
‚Ä¢ Online obituary search.     
‚Ä¢ Should the participant  continue to be unreachable, they will be considered lost to 
follow -up.  
 
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 [ADDRESS_96680] be verified prior to randomiza tion (refer to the MOP for details ). Sites will be 
responsible for notifying the coordinating center for participant withdrawals, lost to follow -up, 
permanent cessation of study drug, study drug dose modifications  (if allowed, per Appendix) , or 
change in vital status. Data will be  collected directly from the participant and supported by 
[CONTACT_30219], as needed.  
  
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 30 8.1. Schedule of Events   
 
Table 1: Schedule of Events  
 
                                              
 
 
 
[ADDRESS_96681] pregnancy listed as a contraindication for females of 
childbearing potential. Participants will self -report pregnancy using the Pregnancy Reasonably Ex cluded G uide.  
3 Review only during study drug/pla cebo administration if contraindicated medications provided for the study drug 
arm, per Appendix .  
4 Day 14 only.  
5 Daily symptom reporting; continued daily beyond day 14 through day 28 until symptoms resolve for >  3 
consecutive days.  
6 Day 7 and 14 only.  
7 Day 3, 7, and 14 only.  
8 Participant‚Äôs medical record will be reviewed to confirm Serious Adverse Events (SAEs), Unanticipated Adverse 
Device Events (UADEs) [as applicable], and Events of Special Interest (ESIs).   
 
 
 
 
 
 
 
 Screening  Intervention 
Period  Follow -up Period  Final 
Visit  Unplanned 
Study Visit  
Day 
Within 2 days 
of Day 1  
Day 1  
Days 2 -14 
 
Day 15 -
20 
Day 21 
¬± 2 days  
Day 22 -
27 
Day 28 
+ 5 
days  
Day 90 
+ [ADDRESS_96682] review  X 
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 31 8.1.1.  Screening  
The following events will occur at Screening : 
‚Ä¢ Consent : Participants will be consented either via an e -consent process  or paper process . 
The consent process should be done in accordance with local  and central  IRB regulations . 
Phone consenting may be facilitated through the e -consent or paper process.  
‚Ä¢ Demographic information will be collected including , but not limited to,  age, sex, race,  
ethnicity , and  occupation  
‚Ä¢ Eligibilit y criteria confirmation  by [CONTACT_88541] 
a paper process  
‚Ä¢ Abbreviated medical history  
‚Ä¢ Self-reported pregnancy, for women of childbearing potential ( only for enrollment in 
Study Drug Appendices that include pregnancy as a contraindication)  
‚Ä¢ Concomitant therapy  
‚Ä¢ Symptom reporting, daily  during screening period 
‚Ä¢ QOL questionnaire  
‚Ä¢ Randomization (see Section 5.3.3) 
8.1.2.  Intervention Period 
The following events will occur during the Intervention Period, starting with receipt of study 
drug/ placebo : 
Day 1:  
‚Ä¢ Receipt of study drug or placebo 
‚Ä¢ Study drug self -administration (see Appendices for specific study drug/placebo 
administration)  
‚Ä¢ Concomitant therapy  
‚Ä¢ Drug adherence questionnaire  
‚Ä¢ COVID -19 Outcomes  
‚Ä¢ Symptom reporting 
‚Ä¢ SAE, UADE (as applicable),  and ESI collection 
Days 2-14: 
‚Ä¢ Study drug self -administration (see Appendices for specific study drug/placebo 
administration)  
‚Ä¢ Concomitant therapy,  including contraindicated medications provided for the study drug 
arm, per Appendix, during study drug/placebo administration.  
‚Ä¢ Remote  visit (Day 14 only ) 
‚Ä¢ Drug adherence questionnaire , daily  
‚Ä¢ COVID -19 Outcomes  (Day 7 and 14 only) 
‚Ä¢ Symptom reporting, daily  
‚Ä¢ QOL questionnaire  (Day 7  and 14  only) 
‚Ä¢ At-home pulse oximetry readings  (Day 3, 7, and 14  only)  
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 32 ‚Ä¢ SAE, UADE (as applicable),  and ESI collection 
8.1.3.  Follow -up Period 
Day 15-20:  
‚Ä¢ Symptom reporting, daily from Day [ADDRESS_96683] not  yet reported three 
consecutive days of no symptoms. Participants who experience three days of 
improvement before Day 14 but who then experience symptoms again will not be 
followed daily.  
‚Ä¢ SAE, UADE (as applicable),  and ESI collection 
Day 21 ¬± 2 days: 
‚Ä¢ COVID -19 Outcomes  
‚Ä¢ Symptom reporting, daily from Day [ADDRESS_96684] not  yet reported three 
consecutive days of no symptoms.  Participants who experience three days of 
improvement before  Day 14 but who then experience symptoms again will not be 
followed daily.  
‚Ä¢ SAE, UADE (as applicable),  and ESI collection 
Day 22-27:  
‚Ä¢ Symptom reporting, daily from Day [ADDRESS_96685] not  yet reported three 
consecutive days of no symptoms. Participants who experience three days of 
improvement before Day 14 but who then experience symptoms again will not be 
followed daily.  
‚Ä¢ SAE, UADE (as applicable),  and ESI collection 
Day 28 + 5 days:  
‚Ä¢ Remote visit 
‚Ä¢ COVID -19 Outcomes  
‚Ä¢ Symptom reporting, daily from Day [ADDRESS_96686] not  reported three 
consecutive days of no symptoms.  Participants who experience three days of 
improvement before Day 14 but who then experience symptoms again will not be 
followed daily.  
‚Ä¢ QOL questionnaire  
‚Ä¢ SAE, UADE (as applicable),  and ESI collection 
8.1.4.  Final Visit  
Day 90 + 5 days:   
‚Ä¢ COVID -19 Outcomes  
‚Ä¢ Symptom reporting 
‚Ä¢ QOL questionnaire  
‚Ä¢ SAE, UADE (as applicable),  and ESI collection 
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 33 8.2. Clinical Assessments 
Abbreviated Medical History : smoking status, estimated body mass index ( BMI)/obesity, pre-
existing underlying lung disease  (e.g. chronic obstructive pulmonary disease , asthma, idiopathic 
pulmonary fibrosis ), underlying immunosuppression (transplant, malignancy, human 
immunodeficiency virus ( HIV), autoimmune disease), medical conditions that may increase risk 
of COVID -19 infections or complications ( e.g., diabetes, cardiovascular disease, hypertension, 
chronic kidney disease ), venous thromboembolism, chronic liver disea se 
Concomitant Medications of Interest:  Concomitant medications of interest, including study drug 
specific contraindicated medications, will be collected. Refer to Section 6.[ADDRESS_96687] and to the study drug specific appendices for contraindicated 
medications.  
Self-reported Pregnancy:  Participants will be asked to self -report pregnancy, as needed, per 
Study Drug Appendix. T he 3-item ‚ÄúPregnancy Reasonably Excluded Guide‚Äù will be used to 
assess pregnancy at screening. The ‚ÄúPregnancy Reasonably Excluded Guide‚Äù uses traditional and 
World Health Organization criteria to exclude pregnancy via participant self -report [14]. Refer to 
the MOP for details.   
Remote  Visit: Designated  study personnel will contact [CONTACT_88542] a phone call or 
other form of direct contact  (e.g. text or e -mail survey)  in order to conduct  study assessments, 
includ ing, but not limited to, COVID -19 outcomes, drug adherence (at Day 14), and safety 
events . A missed remote visit will be considered a protocol deviation (non-major) . If a 
participant misses a remote visit, site study staff should take immediate action to c ontact the 
participant, per Section 7.3 follow -up processes. Refer to the MOP for details.   
Drug Adherence:  Adherence to the study drug administration schedule will be collected via the 
online system  and confirmed at the Day 14 remote  visit. 
COVID -19 Outcomes : The COVID -19 outcomes  for this trial are based on the World Health 
Organization‚Äôs Ordinal Scale for Cl inical Improvement and will be collected via the online 
system  and from the medical record . [15] The following outcomes will be assessed as part of the 
COVID Clinical Progression  Scale:    
0. No clinical or virological evidence of infection  
1. No limitation of activities  
2. Limitation  of activit ies 
3. Hospi[INVESTIGATOR_057] , no oxygen therapy 
4. Hospi[INVESTIGATOR_057] , on oxygen by [CONTACT_88543]  
5. Hospi[INVESTIGATOR_057] , on non-invasive ventilation or high-flow oxygen 
6. Hospi[INVESTIGATOR_057] , on intubation and mechanical ventilation  
7. Hospi[INVESTIGATOR_057], on ventilation + additional organ support ‚Äì pressors, RRT, ECMO  
8. Death  
Symptom Reporting:  Symptoms and symptom -related responses will be reported by [CONTACT_88544] . Additional symptom reporting may occur from the sites, as 
available.  Each of pre-defined symptoms will be assessed on an ordinal severity scale of none, 
mild, moderate, and severe.  The following symptoms will be collect ed:  
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 34 ‚Ä¢ Fatigue  
‚Ä¢ Dyspnea - shortness of breath or difficulty breathing at rest or with activity 
‚Ä¢ Fever  
‚Ä¢ Cough  
‚Ä¢ Nausea  
‚Ä¢ Vomiting  
‚Ä¢ Diarrhea  
‚Ä¢ Body aches  
‚Ä¢ Sore throat  
‚Ä¢ Headache 
‚Ä¢ Chills  
‚Ä¢ Nasal symptoms  
‚Ä¢ New l oss of sense of taste or smell  
‚Ä¢ Other COVID -related symptom   
At-home pulse oximetry measurements : Participants will provide pulse oximetry readings using 
a study-provided FDA -approved  pulse oximeter. Two consecutive pulse oximetry readings must 
be reported at each required timepoint. Day 3, 7, and Day 14 are study-required timepoints for 
pulse oximetry readings. Participants can  report pulse oximetry readings at other times 
throughout the study, at their own discretion.   
8.3. Quality of Life Questionnaires  
The following Q OL questionnaire will be used in this study:  
‚Ä¢ Modified PROMIS -29: PROMIS  measures were developed through a collaborative 
process funded by [CONTACT_18121].  [16] The PROMIS -29 consists of seven health domains with 
four 5-level items  associated with each and a pain intensity assessment using a 0-10 
numeric rank. The seven health domains include physical function, fatigue, pain 
interference, depressive symptoms, anxiety, ability to participate in social roles and 
activities, and sleep disturbance . [17] The PROMIS -[ADDRESS_96688] questions from each of the seven health domains, refer to the 
MOP for details.  
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 [ADDRESS_96689] of a clinical trial. An AE can therefore be any change in clinical 
status, routine labs, x-rays, physical examinations, etc., that i s considered clinically significant by 
[CONTACT_1704] .  
An SAE or serious suspected adverse reaction or serious adverse reaction as determined by [CONTACT_88545]:  
‚Ä¢ Death   
‚Ä¢ Life-threatening AE (‚Äúlife -threatening‚Äù means that the study participant was, in the 
opi[INVESTIGATOR_26335], at immediate risk of death from the reaction as it 
occurred and required immediate intervention)  
‚Ä¢ Persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions  
‚Ä¢ Inpatient hospi[INVESTIGATOR_1081]  
‚Ä¢ Congenital abnormality or birth defect  
‚Ä¢ Important medical event that may not result in one of the above outcomes, but may 
jeopardize the health of the study participant or require medical or surgical intervention 
to prevent one of the outcomes listed in the above definition of serious event  
Hospi[INVESTIGATOR_5187] a preexisting condition that did not worsen from 
baseline does not meet the definition of an SAE. Hospi[INVESTIGATOR_31561] a stay in the 
hospi[INVESTIGATOR_88489] [ADDRESS_96690] (ADE) and Unanticipated Adverse Device Effect (UADE) 
For those repurposed medications that are a part of a combination product, which includes a drug and a device, the following additional definitions will apply.  
An ADE is an AE  related to the use of an investigational medical device. This includes any AE 
resulting from insufficiencies or inadequacies in the instructions for use, the deployment, the implantation, the installation, the operation, or any malfunction of the repurposed medical 
device. This also includes any event that is a result of a use error or intentional misuse.  
‚Ä¢ Device malfunction ‚Äì the failure of a  device to perform in accordance with the 
instructions for use or clinical investigative plan.  
‚Ä¢ User error or intentional misuse - A device is used in a manner that is an act or omission 
of an act that results in a different medical device response than intended by [CONTACT_88546].  
A UADE is any SAE caused by, or associated with, a device, if that effect, problem, or death 
was not previously identified in nature, severity, or degree of incidence in the investigational 
plan or applications (including a supplemental plan or appli cation), or any other unanticipated 
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 36 serious problem associated with a device that relates to the rights, safety, or welfare of 
participants.  
Unanticipated Adverse Device Effects  (UADEs)  will include events meeting either A or B as 
stated below:  
A. Events meeting ALL of the following criteria:  
‚Ä¢ Not included in the relevant appendices or Product Label  
‚Ä¢ Related to the device per site PI [INVESTIGATOR_1238]/or IND sponsor  
‚Ä¢ Serious (meets any of the following criteria):  
o Is life -threatening illness or injury 
o Results in permanent i mpairment of a body function or a body structure  
o Necessitates medical or surgical intervention to prevent permanent 
impairment of a body function or a body structure  
o Results in hospi[INVESTIGATOR_3094]  
o Led to fetal distress, fetal death, or congenital abnormality or birth defect  
o Led to death 
(Permanent means irreversible impairment or damage to a body structure or function, exclu ding 
trivial impairment or damage ). 
B. Any other unanticipated serious problem associated with the device that relates to the 
rights, safety, or welfare of participants.  
9.1.2.  Collection Period for  AE and SAE Information 
Study participants (and their designated emergency proxies) will be instructed to report ESIs, 
SAEs , and UADEs through their access t o the study‚Äôs online system . Each day for 14 days, the 
participant will be  asked to report on their symptoms and health state, including hospi[INVESTIGATOR_65586]/or other change in health condition. The assessments include specific questions pertaining to 
ESIs, as well as symptoms and seve rity, health care visits, medications and a notification to the 
participant to contact [CONTACT_88547]. If the participant is still 
report ing symptoms at Day 14, they will continue to be assessed until they have experienced 
three consecutive days without symptoms, or until Day 28, whichever is shorter. At Day [ADDRESS_96691] from the study team, or to report any unusual 
circumstances that might be relevant, if they so wish. Failure to complete daily as sessments is 
also a trigger for review of a possible SAE. A missed assessment  on the day after receiving the 
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 [ADDRESS_96692] dose of  study medication (Day 2) or any two consecutive days of missed assessments up to 
Day [ADDRESS_96693] access to event 
reporting via the online system  from the signing of the informed consent form (ICF)  until the 
Final Visit (Day 90). 
Events of special interest (ESIs) and SAEs  will be  extracted by [CONTACT_88548]‚Äôs medical record  if the participant seeks medical care or if hospi[INVESTIGATOR_88490] , 
each of which notifies the site  to conduct follow up.   
Medical occurrences that begin before the start of study drug/placebo,  but after obtaining 
informed consent , will not be considered an AE.  
Non-serious AEs (or ADEs, as applicable)  may be reported by [CONTACT_2299], but will not be 
further assessed by [CONTACT_88549] E SI.  
Events of Special Interes t (ESIs),  SAEs , and UADEs (as applicable)  will be collected from the 
start of study drug/device combination until the Final Visit (Day 90) or until [ADDRESS_96694] dose /use of device  if participant terminates the study early . 
9.1.3.  Assessing Causality of a Serious Adverse Event  
If an SAE occurs, t he site investigator  or medical monitor  will assess the relationship to study 
drug by [CONTACT_88550]:  
‚Ä¢ Related:  
o Study drug - there is a temporal relationship between study drug and event onset 
or the event abates when study drug is discontinued or known to occur with study 
drug.  
o Device ‚Äì an event is due to the use of the device and cannot be reasonably 
explained by [CONTACT_88551].  
‚Ä¢ Not related: The event has no temporal relationship to study drug (or study device, as 
applicable)  or the AE  (or ADE, as applicable)  has a much more likely alternate etiology 
or is due to an underlying or concurrent illness or effect of another drug (or device, as 
applicable) . 
9.1.4.  Reporting and Monitoring of SAEs  
All of the study drugs used in this platform  protocol are repurposed medicati ons that are 
approved for marketing in the US  for another medical condition. However, their investigational 
use for treatment  of COVID -[ADDRESS_96695] to IND regulations in 21 CFR 312. The IND  sponsor or designee will review SAEs 
weekly, and will perform aggregate reviews of SAEs every two weeks. The IND sponsor or her 
designee will be responsible for determining if the safety reporting criteria are met per 21 CFR 
312.32(c)(1)(i)( C) and 21 CFR 312.32(c)(1)(iv) and will notify the Data Coordinating Center 
(DCC) to prepare an aggregate report for submission to the FDA. An aggregate safety report will 
be submitted to FDA as soon as possible, but in no case later than 15 calendar days after the IND 
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 [ADDRESS_96696] from the Agency following the submission of any 
aggregate reports.  
Any UADE(s) that the IND sponsor determines is/are reportable will be submitted to the FDA, 
manufacturer, all reviewing IRBs, and all participating investigators within [ADDRESS_96697].  
All hospi[INVESTIGATOR_88491] (see Section 10.9), any event that is 
determined to be COVID -19-related will not be reportable as an expedited SAE. All events that 
are not COVID -19-related per the adjudication process will be reviewed by [CONTACT_88552] a reportable SAE.  
Individua l S AEs and UADEs must be entered into the data system within 24 hours of site 
awareness. The DCRI Safety Surveillance  team  will notify pharmaceutical partners of SAEs 
within 1 business day of their receipt that occur involving the specific appendix of the supplied 
study drug/placebo,  as required.  Serious Adverse Events that are related and confirmed unlisted 
by [CONTACT_88553]; as  7-day reports 
for unexpected fatal or life -threatening adverse reactions and 15-day reports for serious and 
unexpected adverse reactions. If the IND sponsor, IDMC , or FDA note a clinically important 
increase in the rate of a S[LOCATION_003]R, the IND sponsor or her de signee will notify investigators no 
later than 15 calendar days after determining that the information qualifies for reporting.  The 
investigator will follow all reportable events until resolution, stabilization or the event is 
otherwise explained. The DCRI Safety Surveillance Team will follow all SAEs until resolution, 
stabilization, until otherwise explained.  
Pregnancies that occur while on-study will be collected and will not be followed to outcome  if 
outcome occurs beyond the participant‚Äôs Final Study Vi sit, however, any associated ESI or SAE 
should be reported if information can be collected and entered into the EDC.  The DCRI Safety 
Surveillance team will notify pharmaceutical partners of a pregnancy within 1 business day of 
receipt that occur involving the specific appendix of the supplied study drug/placebo,  as 
required.  
9.1.5.  Events of Special Interest  
The following are also considered E SIs to the study and will be collected by [CONTACT_88554][INVESTIGATOR_88492] :  
‚Ä¢ Hypoxia, defined as two consecutive pulse oximetry readings ‚â§ 93%  
Each study drug may have a unique list of possible related ESIs. Refer to the relevant 
appendices.  
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 39 9.2. Unanticipated Problem ( UP) and Terminations  
9.2.1.  Definition of Unanticipated Problem   
The OHRP considers UPs involving risks to participants or others to include, in general, any 
incident, experience, or outcome that meets all of the following criteria:  
‚Ä¢ Unexpected in terms of nature,  severity, or frequency given (a) the research procedures 
that are described in the protocol -related documents, such as the IRB -approved research 
protocol and informed consent document; and (b) the characteristics of the participant 
population being studie d. 
‚Ä¢ Related or possibly related to participation in the research (‚Äúpossibly related‚Äù means there 
is a reasonable possibility that the incident, experience, or outcome may have been 
caused by [CONTACT_3459]).  
‚Ä¢ Suggests that the resear ch places participants or others at a greater risk of harm (including 
physical, psychological, economic, or social harm) than was previously known or recognized.  
9.2.2.  Reporting of an Unanticipated Problem   
The site investigator will report UPs for their partici pants to the DCC. The site may also be 
required to inform their reviewing IRB about a UP occurring at the local institution. The UP 
report to the DCC will include the following:  
‚Ä¢ A detailed description of the event, incident, experience, or outcome  
‚Ä¢ An expl anation of the basis for determining that the event, incident, experience, or 
outcome represents an UP  
‚Ä¢ A description of any changes to the protocol or other corrective actions that have been 
taken or are proposed in response to the UP  
‚Ä¢ The DCC will documen t and review all UPs.  Details of the UP reporting process will be 
located in the MOP.  
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 [ADDRESS_96698] 
improved COVID -19 symptoms as compared to those who receive placebo.  
10.2. Sample Size Determination  
This study is designed to be analyzed using a Bayesian approach, accepting the possibility of adding and droppi[INVESTIGATOR_88493]. There is also the potential for extending 
accrual in a study  drug appendix if there is the potential to demonstrate benefit on clinical 
events. Detailed simulations will be used to demonstrate the operating characteristics of each study drug appendix. Decision thresholds will be set to balance overall power with control of 
the Type I error rate. To aid planning for this trial, symptom count  and clinical event data were 
estimated from participants in a clinical trial with similar inclusion criteria. Data were not 
collected daily i n that study, but evaluations were completed on Day 10 after randomization, 
which is considered a clinically meaningful point in time. Based on the observed distribution, it 
is estimated that  studies of about n= 600 (300 study drug and 300 placebo)  will be sufficiently 
sized to determine whether there is evidence of meaningful benefit with >85% power ( Table 2). 
Moreover, when a  study drug demonstrates overall effectiveness, the planned adaptations to 
increase targeted accrual for the purpose of demonstrating benefit on clinical events is a reasonab le extension within the context of this platform. This study will enroll up to 15,000 
adults, depending on the number of study drug appendice s that are added and adjustments to 
sample size depending on the data.  
[18]  
Table 2: ACTIV -6 Sample Size Estimates and Power  
OR Corresponding 
difference in mean 
s ymptom burden  Power  Corresponding Risk Difference in clinical 
ev ents  Power  
80%  85%  90%  80%  85%  90%  
0.4 2.10 75 86 101 0.025  343 392 459 
0.5 1.98 132 150 176 0.021  455 520 608 
0.6 1.86 242 277 324 0.017  675 772 903 
0.7 1.74 496 567 664 0.012  1004 1148 1343 
0.8 1.61 1267 1449 1696 0.009  1652 1889 2211 
The sample sizes given are the sample size for the study drug  arm only. Placebos will be borrowed across study drug 
appendices . The total size of the placebo arm  will be equal to the size of the study drug  arm. The total number of 
placebos in the trial will depend on eligibility of participants among the study drug appendices  and the number of study 
drugs . The calculations are ba sed on symptom burden, hospi[INVESTIGATOR_059], and death at Day 10.  
10.3. Randomization  
See Section 5.3.3 for additional details.   
10.4. Blinding  
The investigators , treating clinicians, and study participants  will all remain blinded to study drug 
versus placebo assignment until after the database is loc ked and blinded analysis is completed. 
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 41 Only the Investigational Drug Service  (IDS ) and staff who are handling randomization codes and 
unblind ed member s of the biostatistical team who are preparing closed IDMC  interim reports 
will be unblinded. The statistical staff responsible for preparing IDMC  reports will not directly 
interact with the clinical team that delivers care to the study participants. Specifically, study 
medication will be dispensed with packaging and labelling that would blind treatment 
assignment. Unblinding will occur only if required for participant  safety or treatment at the 
request of the treating clinician.  
The web-based randomization system  will include  blind-breaking instructions. Partici pant safety 
must always be the first consideration in making an unblinding determination. If the investigator 
decides that unblinding is warranted, the investigator should contact [CONTACT_88555]/placebo for unblinding a participant‚Äôs inter vention assignment .  
10.5. Populations for Analyses  
Modified Intention to Treat ( mITT) Population:   
‚óè All participants  who receive study drug/placebo . 
‚óè Participants who do not receive study drug, for any reason, will be excluded; while this modifies the intent ion to treat principle,  the failure of delivery of medications from site to 
participant is not under the control of either investigator nor participants and is expected 
to occur infrequently and randomly. All other participants will be included, and they will  
be analyzed according to which arm they were assigned. Thus, the m ITT analysis set 
includes all participants  who were randomized and received the study drug.  
Safety Population:  
‚óè The s afety population will include those persons in the  mITT popula tion who re port 
taking at least one dose of study drug or matching placebo. In the unlikely case a 
participant receives the incorrect study drug, participant s will be grouped according to the 
treatments that they received.  
10.6. Statistical Analyses  
The Statistical Analysis Plan ( SAP) for a s tudy drug appendix will be finalized prior to the first 
interim analysis.  It will include a more technical and detailed description of the statistical 
analyses outlined in this section, including detailed simulations used to inform the sample size estimates. This section is a summary of the planned statistical analyses of the most important 
endpoints including primary and secondary endpoints.  
10.6.1.  Ge ne ral Considerations  
Baseline demographic and clinical variables will be summarized for  each randomized arm of the 
study. Descriptive summaries of the distribution of continuous variables will be presented in terms of percentiles (e.g., median, 25th and 75th percentiles) along with means and standard 
deviations. Categorical variables will be  summarized in terms of frequencies and percentages. 
Histograms and boxplots may be used to visualize the data.  
The primary analysis for this study will use a covariate adjusted statistical model . The primary 
outcome is an ordinal variable, which is the co unt of symptoms with hospi[INVESTIGATOR_88494] -6 Protocol [v2.0] 
 
 [ADDRESS_96699] of concurrently randomized participants that meet the 
inclusion and exclusion criteria for that study drug.  
The ge neral form of the Proportional Odds - model can be stated in terms of covariates X and an 
outcome variable Y, where probabilities of outcome value y or greater are given by 
[CONTACT_88556](ùëåùëå‚â•ùë¶ùë¶|ùëãùëã)=expitÔøΩŒ±ùë¶ùë¶+ùëãùëãŒ≤ÔøΩ‚Äàwhere Œ±ùë¶ùë¶ is the intercept for outcome value  y and expit is the 
logistic (inverse logit) transformation. X contains baseline covariates and treatment. The 
coefficients Œ≤ represent the log OR associated with the effects of each adjustment variable, 
including arm assignment. Specifically, the OR represents the relati ve effect of study drug versus 
placebo on the odds Pr (ùëåùëå‚â•ùë¶ùë¶|ùëãùëã)(1‚àíPr(ùëåùëå‚â•ùë¶ùë¶|ùëãùëã)) ‚ÅÑ , for any value y. 
The proportional odds is attractive for the analysis of ordinal and quantitative response variables, 
such as the primary outcome, because they directly model the cumulative distribution function from which the many summaries of the primary outcome in each study drug arm are easily 
derived. Example summaries are the probability of a participant being symptom free, and the 
probability of being hospi[INVESTIGATOR_88495].  
The proportional odds model can be extended to accommodate repeated measures over time for 
individual participants. A longitudinal framework allows one to model the course of disease. 
There are several approaches to taking into account repeated measurements, among which a first -
order Markov state transition model for ordinal outcome provided the best fit to the correl ation 
structure found in data from the ORCHID trial. While these pa rticipants  had more severe  disease 
and the outcome was clinical in nature, the  same considerations  apply to the within-participant  
correlation structure  for symptoms, hospi[INVESTIGATOR_30059]. T he longitudinal ordinal 
proportional odds model  will be fit using a Markov state transition model.   
With a first -order Markov process, the outcome on one day of measurement becomes the 
predictor for the next day of measurement. The model will also take absolute time (days from 
first dose of study drug) into account because the mix of outcomes changes over time in a way 
that simple transition odds ratios cannot capture. The selected approach allows the correlation 
between states on two successive days to be high within pa rticipant, and it handles absorbing 
states such as death.  It also allows the consideration of different time intervals between 
measurements (if measurement days are missed).  
Markov models typi[INVESTIGATOR_88496] (time 
zero). This the case for ACTIV -6. Participants cannot inhabit the extremes of the scale at 
enrollment, and that is of no consequence. The main obstacle to using transition models is that 
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 43 the primary model parameters (for the proportional odds model) at one time are conditioned on 
the previous state. The model will be restated to obtain probabilities of being in state y or worse 
(‚Äústate occupancy probabilities‚Äù) through recursive (through time) matrix multiplications to 
‚Äúuncondition‚Äù the transition probabilities. Thus, the OR and the probability of being in any given 
state (or worse) can be provided for any day. The probabilities will be leveraged for quantifying 
the effect of study drugs  on symptom burden, hospi[INVESTIGATOR_059], and death.  For example, it is 
possible to state the probability of having more than [ADDRESS_96700] sizes  
(Table 2), an OR of 0.6 would be observed as an absolute difference in the probability of being 
hospi[INVESTIGATOR_88497] 0.017 (1.7%) . 
State occupancy pr obabilit ies are functions of all model parameters. Because of that it is difficult 
to get confidence intervals and statistical tests using frequentist methods. The Bayesian approach  
will be used  to provide  exact inferences, taking all uncertainties into account. Graphical methods 
will be used to show the probability of a pa rticipant  being either symptom free, or of being 
hospi[INVESTIGATOR_88495], as a function of time and treatment (these figures are sometimes referred 
to as funnel plots). Various ways of rest ating the model results are also possible. For example, if 
considering the state occupancy probabilities for mortality, this would approximate a Cox 
proportional hazards model.  
The common OR will be used as the primary estimand for claims of effectiveness  in reducing 
symptom s. The probability of hospi[INVESTIGATOR_88498]. These are the primary estimands for decision making in this trial, and both they and their posterior distribution are readily computed using standard Bayesian methods. Mean and 
median  time to symptom freedom will be used to quantify the clinical benefit of symptom 
improvement.  
In the modeling, the proportional odds assumption will be checked. While the model is generally 
robust, a check will be done for the possibility of a different treatment effect on clinical events 
than on symptoms and a partially proportional model will be used if it does differ. The time by 
[CONTACT_88557]  14-
day observation window . If it does, the decision making in this trial will be anchored to the OR 
observed on Day 14.  
10.6.3.  Mode l priors  
Prior distributions will be specified as follows: 
- Intercepts  are derived parameters from the multin omia l outcome cell probabilit ies 
having a Dirichlet distribution with concentration parameter 1(‚ÅÑ0.80+0.35 max  (ùëòùëò,3)), 
found to have excellent properties (here k = total number of outcome categories)  
- The covariate X is an indicator variable for being in the study drug arm  (versus matching 
placebo), and the study drug effect  (negative values indicate benefit) has a skeptical 
prior which is a normal distribution having mean zero and small standard deviation [ SD] 
(concentrating the treatment effect towards z ero) provided below.  

CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 [ADDRESS_96701]. Assume that the investigational 
study drug is not a cure but is rather an incremental therapy. This implies that the odds ratio OR 
  for the study drug cannot be near zero (values < 1.0 indicate benefit).  Assume that the 
probability of a large benefit on the outcome severity, with large meaning an OR < 0.5, is only 
0.025, and to be symmetric the chance of large harm (OR > 2) is also 0.025.  Thus, the prior 
probability that the OR is in [ 0.5, 2] is 0.95. The prior SD  that achieves this level of skepticism 
is log (0.5)Œ¶‚àí1(0.025 ) ‚ÅÑ  where  denotes the standard normal cumulative distribution function.  
10.6.4.  Assessing Effectiveness 
The overall effect of each study drug versus matching placebo will be quantified using the 
common OR from the proportional odds model (primary estimand). Evidence for efficacy will be 
quantified as the posterior probability that the OR is less than 0.9. This is denoted the ‚Äúposterior 
probability for efficacy‚Äù or ùëÉùëÉ (ùëÇùëÇùëÇùëÇ<0.9|Data ). Similar ly, the risk difference in hospi[INVESTIGATOR_88499]. Regardless of whether there is 
an efficacy signal, the following quantities will be reported from the model:  
‚Ä¢ Mean and median time to symptom freedom  (for quantifying benefit on symptoms)  
‚Ä¢ Mean and median time to hospi[INVESTIGATOR_30059] (secondary outcomes)  
The primary analysis will be implemented separately for each study drug, where the matching 
placebo arm will consist of concurrently randomized participants that meet the inclusion and 
exclusion criteria for that study drug.  An mITT approach will be used  for primary analyses. All 
available data will be used to compare each  study drug versus placebo control, regardless of 
post-randomiza tion adherence to study protocols.  
10.6.5.  Planned Interim Analyses, Early Stoppi[INVESTIGATOR_007], and Type -I Error Control  
Individual study drugs may require different sample sizes, and the sample sizes may be adjusted 
based on the results of interim analyses. Therefore, fixe d enrol lment triggers will be used for 
interim analyses. An interim analysis will occur after enrol lment and completion of 14 day 
follow up of approximately every 200 participants in a study arm  (100 in study drug arm and 100 
in placebo arm) . At each inter im analysis, the study drug appendix may be stopped early for 
efficacy or futility. Thresholds have been established to guide stoppi[INVESTIGATOR_88500], there is evidence of equivalence, there is evidence of sympt om 
benefit but pursuing clinical benefit is futile, or if the study drug is harmful. The following 
decision thresholds will be checked at each interim analysis:  
i) The Study Drug is found to have benefit (efficacy): A posterior probability of 
meaningful be nefit (e.g. OR < 0.9) for a study drug in comparison to the placebo control 
of > 0.95 will result in a declaration of overall superiority.  
a. If a study drug arm is declared superior, a futility analysis will be 
conducted on observing clinical efficacy (reduction in hospi[INVESTIGATOR_88477]) if 
the study drug arm were to continue for an additional one year. Accrual will be 
projected based on ac tual trial accrual and projected case rates. Stoppi[INVESTIGATOR_88501] -6 Protocol [v2.0] 
 
 45 futility will be strongly encouraged if the predicted probability of success (PPOS) 
is low (e.g. <0.1) and will be discouraged if the PPOS is high (e.g.>0.7).   
ii) The study drug is found to be substantially similar to the placebo control 
(inefficacy): A posterior probability of >0.95 that there is no more than trivial benefit (e.g. OR > 0.9) or harm of an arm will result in termination of that arm.  
iii) The study drug is found to cause harm (infer iority): A posterior probability of 
>0.85 for worse adverse clinical outcomes (hospi[INVESTIGATOR_30059]) for a study drug 
relative to the placebo control (e.g. a risk difference >0.01) will result in termination of 
that arm.  
iv) The predicted probability of success of any study drug given expected accrual at a 
prespecified point in time will be provided to the IDMC . Stoppi[INVESTIGATOR_88502] (e.g. <0. 1) and will be discouraged if the PPOS is 
high (e.g. >0.7).  Note  that unlike the probability of inefficacy, PPOS involves Bayesian 
posterior predictive distributions.  
Futility is a low probability of achieving any conclusions within a reasonable time frame or with 
available resources. Prior to each interim analysis, th e target date for study completion will be 
specified, and accrual will be projected by [CONTACT_88528]. A statistical model may be used to predict accrual.  Futility assessment will use the lowest of either the planned accrual or predicted 
accrual at study  closure.  
The combination of decision thresholds and effect sizes have been selected to balance the ability to observe a meaningful effect on symptoms, to observe the potential for an effect on clinical 
outcomes, and to maximize power. In making decisions,  power  will be balanced  with the Type [ADDRESS_96702] 5%.   
10.6.6.  Sensitivity and Supplementary Analyses  
The proportional odds assumption of the model requires that the effect of treatment on the odds 
that Y ‚â• 3 (measured as an OR  versus placebo) is the same relative effect as for Y  ‚â• 4. Even 
when the proportional odds assumption is strongly violated, the estimated O R remains a simple 
function of the Wilcoxon-Mann-Whitney U -statistic, namely the probability that a randomly 
chosen pa rticipant on treatment B has a higher response than a randomly chosen pa rticipant on 
treatment A,
[ADDRESS_96703] to the proportional odds assumption. This assumption will be relaxed using a 
partially proportional odds model as necessary.  
In addition to checking assumptions about the modeling approach, association of adherence with 
outcomes  will also be ascertained . In the main statistical mode l, the number of doses of study 
drug consumed will be added  as a covariate.  
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 [ADDRESS_96704] and their uncertainties across age = 10, 11, ‚Ä¶, 100. Differential 
treatment effects by [CONTACT_4321], body mass index, and age will be examined.  
Studies under this master protocol will be sized only for assessing overall study drug effects. 
Thus, there may be inadequate power to (1) examine interactions and to (2) estimate covariate -
specific treatment effects (e.g., odds ratio at age 70 or for females ). 
10.6.8.  Secondary Clinical Endpoint  
The COVID Clinical Progression  Scale score on Day 14  will be compared between participants  
in each study drug arm and the placebo arm  using a covariate adjusted proportional odds model . 
A similar approach will be used for QOL outcomes. Covariates will be prespecified and will 
include at a minimum: age, baseline severity, and duration of illness . The proportional odds 
assumption will mainly be examined using graphical methods ‚Äîe.g., the logit of the empi[INVESTIGATOR_88503] . If proportionality is clearly violated, a partial proportional odds or non-proportional 
odds models  will be considered . As before, a Bayesian approach to model interpretation will be 
used.  For estimating time to symptom freedom based on the definition of at least three 
consecutive days without symptoms, a proportional hazards model will be used. Since death is a 
competing risk, cause-specif ic hazards  will be estimated . Observations will be censored at [ADDRESS_96705] of treatment on long term outcomes, the SAP will describe how participant  state during the intervention period will  be used to inform longer term 
outcomes.  
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 47 10.6.10.  Adherence and Retention Analysis  
Withdrawals from study drug and consent withdrawals will be tracked via the online system .  
Participants will be asked about  their use of study drug. Those reporting discontinuation or 
switching will be asked about the reasons for discontinuation/switching.   
Measures of study retention to inform follow -up time will be based on several measures, 
including web-based check -ins for symptoms and COVID -19 outcome reporting.  
10.7. Inte rim Reporting   
In addition to routine evaluation of decision thresholds pursuant to the statistical design of this 
study, regular IDMC  reviews will be conducted to ensure the safety of study participants.  
Regular IDMC  meetings will monitor the following parameters at a minimum:  
‚Ä¢ Recruitment progress  
‚Ä¢ Enrollment overall and by [CONTACT_12125]  
‚Ä¢ Adherence, retention, and status of data collection 
‚Ä¢ Events of special interest  (ESIs) 
‚Ä¢ Unanticipated problems  
‚Ä¢ Serious adverse events  (SAEs)  
Interim exami nation of clinical endpoints will be based on the accrual of primary endpoint data.  
It is expected that reviews of the data will occur approximately after each 2 00 participants  are 
enrolled in each study drug appendix (100 in study drug arm and 100 in placebo arm) .  
For ethical reasons, interim examinations of key safety and process data will be performed at 
regular intervals during the course of the trial. The  DCC will create reports to track parti cipan t 
enrollment, rates of adherence with the assigned  treatment strategy, and frequency of protocol 
violations. Prior to each meeting, the DCC will conduct any requested statistical analyses and 
prepare a summary report along with the following information: pa rticipant enrollment reports, 
rates of adherence with the assigned treatment, and description of SAEs.  
Safety reports will be prepared for the IDMC  approximately weekly once enrollment begins. The 
prespecified stoppi[INVESTIGATOR_88504] a  strict rule for early termination.  It is expected that both internal and external factors will 
influence the decisions of the IDMC . The SAP will describe the planned interim analyses and 
futility monitoring in detail . 
10.8. Independent Data Monitoring Committee  (IDMC) 
The IDMC  will monitor participant safety and study performance. A n IDMC  charter that outlines 
the operating guidelines for the committee and the procedures for the interim evaluations of 
study data will be developed and agreed upon by [CONTACT_31849] . Reports will be prepared by [CONTACT_88558], or as requested by [CONTACT_88559], and 
will include interim analyses of primary and secondary endpoints, additional safety events, and 
other information as requested by [CONTACT_942]. After each scheduled closed meeting, the 
IDMC  will send a recommendation to the IND sponsor  to continue, modify,  or terminate  the 
study. After approval, the recommendations will be forwarded by [CONTACT_88560] -6 Protocol [v2.0] 
 
 48 (CCC) to investigators for submission to their local, regional and national IRB /Ethic 
Committees, as applicable. Please refer to the IDMC  Charter for further details . 
10.9. Adjudication Committee  
The medical records  will be requested  for all participants reporting a hospi[INVESTIGATOR_5478]/or de ath 
at any point during the study. For each participant -reported hospi[INVESTIGATOR_88505], t he 
DCRI Clinical Ev ent Ascertainment (CEA)  group will review the medical records and confirm 
the oc currence and root cause of the event as part of an adjudication process . The CEA group 
includes specialists relevant to the hospi[INVESTIGATOR_88506], additional details 
about review procedures will be provided in an adjudication charter.   
 
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 [ADDRESS_96706] (IRB)  
The protocol, ICF(s), recruitment materials, and all participant materi als will be submitted to the  
IRB(s) of record  for review and approval . This approval must be obtained before any participant 
is enrolled. Any amendment to the protocol will require review and approval by [CONTACT_1201](s) 
before being implemented in the study. All changes to the consent form will also be IRB -
approved and a determination will be made regarding whether previously consented participants 
need to be re -consented.  
11.2. Informed Consent Process  
All consenting will occur either via an electronic consent process  or a paper process . Consent 
forms describing in detail the study drug/placebo,  study procedures, and risks will be  given to the 
participant and documentation of informed consent is required prior to starting study procedures. 
Informed consent is a process that is initiated prior to the individual‚Äôs agr eement  to participate in 
the study and continues throughout the individual‚Äôs study participation. A description of risks 
and possible benefits of participation will be provided to the participants. Consent forms will be 
IRB-approved and the participant will be asked to read and review the document. The participant 
will be  provided a phone number and email in the event they have questions about study 
participation. This will allow them to communicate with the investigator s (or their delegate) , for 
further  explana tion of the research study and to answer any questions that ma y arise , as 
necessary . Participants will have the opportunity to carefully review the consent form and ask 
questions prior to signing.  
The participants should have the opportunity to discuss the study and think about it prior to agreeing to participate. Th e participant will sign the informed consent document prior to any 
procedures being done specifically for the study. The participants may withdraw consent at any 
time throughout the course of the study. A copy of the informed consent document will be 
provi ded to the participants for their records. The rights and welfare of the participants will be 
protected by [CONTACT_40749].  
The study team will distinguish between the desire to discontinue study drug and the desire to 
withdraw consent for study follow -up. In the event that a participant withdraws consent, the 
investigator or his /her designee will clarify with the participant and document whether the 
withdrawal is temporary or permanent, and if a full or partial withdrawal.  
11.3. Participant and Data Confidentiality  
Participant confidentiality is strictly held in trust by [CONTACT_3486], their staff, 
and the sponsor(s) and thei r agents. This confidentiality is extended to cover testing of biological 
samples in addition to the clinical and private information relating to participants. Therefore, the study protocol, documentation, data, and all other information generated will be held in strict 
confidence. No information concerning the study or the data will be released to any unauthorized 
third party without prior written approval of the sponsor. The study participant‚Äôs contact 
[CONTACT_88561] s tudy database.  
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 [ADDRESS_96707] as possible. A four-step, multi -functional approach to quality control  will be 
implemented : 
‚Ä¢ Training: Prior to the start of enrollment, the clinician investigators and key study 
personnel  at each site will b e trained with the clinical protocol and data collection 
procedures, including how to use the Electronic Data Capture (EDC) system. F ollow -up 
training and training for new study personnel or new versions of the protocol will be 
conducted as needed.  
‚Ä¢ Monitor ing: The CCC, along with the DCC, will ensure that data collection is handled 
properly, will provide in-service training, and will address questions from site investigators and coordinators. Electronic r eview  of data quality and completeness  will occur  on a 
regular and ongoing basis. Any issues will be address ed. At a minimum, s ource document 
verification will occur, as needed, for confirmation of COVID -19 diagnosis and 
hospi[INVESTIGATOR_059](s).  
‚Ä¢ Managing data: After the data have been transferred for statistical summarization, data 
description, and data analysis, further crosschecking of the data will be performed with 
discrepant observations being flagged and appropriately resolved through a data query 
system.  
‚Ä¢ Reviewing data: Data regarding e vents of interest wil l be reviewed  to ensure appropriate 
documents are collected for DSMB review. The DCC will monitor standardized 
classification of symptoms  and contact [CONTACT_88562] . 
11.5. Site Monitoring  
This study will employ a centralized risk -based approach to monitoring with routine and periodic 
review of participant -submitted data to validate the informed consent process, select eligibility 
criteria, hospi[INVESTIGATOR_059], identify and follow -up on missing data, inconsistent data, data outliers, 
etc. and ensure completion of administrative and regulatory processes.  The study team will 
facilitate regular communication through training sessions, teleconferences, videoconferencing, 
email, etc. Using quality -by-design principles , steps  will be  taken at the study design stage to 
foresee and limit problems that might occur during the study conduct. Follow -up from the online 
system  and call center is expected to keep participants engaged. Minimal levels of intervention 
and a focus on observing rather than influencing the study participants greatly increases the 
likelihood that Good Clinical Practices will be followed. Central statistical monitoring is 
particularly useful for identifying unusual patterns in data. An integrated approach to quality 
surveillance  will be deployed, which will be detailed in the appropriate study management plans.  
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 [ADDRESS_96708] ( HIPAA) compliant.  
Site personnel  or participants will enter study data into a secure online database. D ata will be 
maintained  in a secure online database unt il the time of study publication. At the time of 
publication, the DCC will generate a de-identified version of the database  for archiving (see 
Section 12.4).  
12.2. Study Records Retention 
Study documents should be  retained for a minimum of six years after the study has ended. 
However, if required by [CONTACT_427], these documents should be retaine d for a longer 
period. No records will be destroyed without the written consent of the sponsor, if applicable. It is the responsibility of the sponsor to inform the investigator when these documents no longer 
need to be retained.  
12.3. Protocol Deviations  
A protocol deviation is defined as  non-c ompliance with the  clinical study protocol, GCP, or 
MOP requirements. The  non-compliance may be on the part of the partici pant, site inv estigator, 
or the si te staff.  
A major  protocol deviation is a significant divergence from the protocol that may have 
significant effect on the participant ‚Äôs safety, rights, or welfare and/or on the integrity of the study 
data. Major protocol deviations  must be sent to the study IRB and l ocal IRB per t heir guidelines, 
recorded in s ource documents, and r eported to the coordinating center. Major protocol deviations 
will be tracked . For this study, any missed or delayed survey completion will not be considered a 
major protocol deviation. Refer to the MOP for details.  
12.4. Publication and Data Sharing Policy  
This study will comply with the NIH Public  Access Policy, which  ensures that the public  has 
access to the results of NIH-funded res earch. Methods of data sharing will include 1) archiving 
de-identified data in a data repository and 2) sharing of limited datasets under a Data Use 
Agreement (DUA) and IRB approval. Data will be made avai lable to qualified investigators by 
[CONTACT_88563] a fully de -identified dataset in  a platform to be determined at the end of the trial . Both 
repositories allow users to search, view study information, and then submit an application to 
receive data. Prior to ar chiving study data, the DCC will produce a final dataset that will be 
stripped of all personal health information (PHI), including full date elements, in c ompliance  
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 [ADDRESS_96709] peer -reviewed 
journals. The International Committee of Medical Journal Editors (ICM JE) member journals have  
adopted a cli nical studies  registration policy as a condition for publicat ion. The ICMJE defines a 
clinical study as  any research project that prospe ctively assigns h uman participants  to 
intervention or concurrent comparison or control groups to study the cause-and-effe ct 
relationship between a medical intervention and a health outcome. The ICMJE  policy, and  the 
Section [ADDRESS_96710] of 2007, req uires that all 
clinical studies be regi stered in  a public  registry such as ClinicalTr ia ls .gov, which is spons ored 
by [CONTACT_88564]. For interventional clin ical trials per formed under  NIH IC 
grants and cooperative agreements, it is the gra ntee‚Äôs responsibility to register the study in an 
acceptable registry, so the research results  may be considered f or publicatio n in ICMJE  member 
journals.  
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 53 13. Study Leadership 
The Steering Committee is a multi -stakeholder committee that oversees the study and includes 
representatives from clinical sites, the trial coordinating center, the NIH, PCORI, Operation 
Warp Speed, the FDA , National Center for Advancing Translational Scie nces (NCATS), ACTIV 
representatives with no conflict of interest, and academic and industry advocates .  
The CCC and DCC are each overseen  by [CONTACT_22660](s). The CCC is responsible for 
study coordination, site management, communication, and financial administrat ion. The DCC is 
responsible for treatment allocations, receipt and processing of data, quality control programs, 
and statistical analysis and reporting.   
An independent IDMC  will oversee the safety and welfare of trial participants as well  as provide 
recommendations for continuation, discontinuation or revision of the trial.  
 
 
Figure 2: Operational Structure Diagram  

CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 54 14. Summary of Changes  
Protocol Version (version #, date)  Summary of Changes  
Version 1.0, 01APR 2021 N/A, Version 1.0  
Version 2.0, 25MAY2021 ‚Ä¢ Added current use of study drug or 
study drug/device combination as an 
exclusion criteria (Sections 1.1 and 
5.2); 
‚Ä¢ Added a  phone call follow -up the day 
after first study drug dose , clarified 
that follow -up w ill occur if two 
consecutive days of reporting are 
missed during Days 3-14,  and added 
that sites/call center will collect missing survey information during 
follow -up calls (Section 7.3); 
‚Ä¢ Added  at-home pulse oximetry 
readings and description of at -home 
pulse oximetry reading collection (Table 1 and Section 8.2); 
‚Ä¢ Added symptom severity scale 
(Section 8.2); 
‚Ä¢ Added Adverse Device Effect and 
Unanticipated Adverse Device Effects 
definitions, collection/reporting period 
details, and causality assessment 
details (Sections 9.1.1, 9.1.2, 9.1.3, 
9.1.4);  
‚Ä¢ Clarified that hypoxia ESI will only be 
collected from hospi[INVESTIGATOR_88507] (Section 9.1.5);  
‚Ä¢ Clarified that any missing or delayed survey completion will not be 
considered a major protocol deviation 
(Section 12.3);  
‚Ä¢ Updated Ivermectin and matched 
placebo information and packaging 
(Sections 16.3, 16.3.1, 16.3.3, 16.4.1);  
‚Ä¢ Added Appendix B ‚Äì Fluvoxamine 
maleate (Section 17); 
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 55 ‚Ä¢ Added Appendix C ‚Äì Arnuity Ellipta 
(fluticasone furoate inhalation 
powder) (Section 18); 
‚Ä¢ Other administrative changes 
throughout.  
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 56 15. Ref er ences  
1. COVID -19 Map FAQ . 2020  [cited 2020; Available from: 
https://coronavirus.jhu.edu/map-faq.html . 
2. McIntosh, K. Coronavirus disease 2019. 2020  [cited 2020 March 24].  
3. Beigel, J.H., et al., Remdesivir for the Treatment of Covid -19 ‚Äî Final Report.  New 
England Journal of Medicine, 2020. 383(19): p. 1813-1826.  
4. Dexamethasone in Hospi[INVESTIGATOR_61013] -19 ‚Äî Preliminary Report.  New 
England Journal of Medicine, 2020.  
5. Gordon, A.C., et al., Interleukin -6 Receptor Antagonists in Critically Ill Patients with 
Covid -19 ‚Äì Preliminary report.  medRxiv, 2021: p. 2021.01.07.21249390.  
6. Baden, L.R., et al., Efficacy and Safety of the mRNA -1273 SARS-CoV -2 Vaccine.  New 
England Journal of Medicine, 2020. 384(5): p. 403-416.  
7. Polack, F.P., et al., Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.  New 
England Journal of Medicine, 2020. 383(27): p. 2603-2615.  
8. Voysey, M., et al., Safety and ef ficacy of the ChAdOx1 nCoV -19 vaccine (AZD1222) 
against SARS-CoV -2: an interim analysis of four randomised controlled trials in Brazil, 
South Africa, and the [LOCATION_006].  The Lancet, 2021. 397([ZIP_CODE]): p. 99-111.  
9. Wang, Z., et al., mRNA vaccine -elicited antibodies  to SARS -CoV -2 and circulating 
variants.  bioRxiv, 2021: p. 2021.01.15.426911.  
10. Grein, J., et al., Compassionate Use of Remdesivir for Patients with Severe Covid-19.  
New England Journal of Medicine, 2020. 382(24): p. 2327-2336.  
11. Beigel, J.H., et al., Remdesivir for the Treatment of Covid -19 ‚Äî Preliminary Report.  New 
England Journal of Medicine, 2020.  
12. McCreary, E.K., J.M. Pogue, and o.b.o.t.S.o.I.D. Pharmacists, COVID -19 Treatment: A 
Review of Early and Emerging Options.  Open Forum Infectious Diseas es, 2020.  
13. Kalil, A.C., Treating COVID -19‚Äî Off-Label Drug Use, Compassionate Use, and 
Randomized Clinical Trials During Pandemics.  JAMA, 2020.  
14. Wyatt, M.A., et al., Implementation of the ‚ÄúPregnancy Reasonably Excluded Guide‚Äù for 
Pregnancy Assessment: A Quality Initiative in Outpatient Gynecologic Surgery.  
Obstetrics & Gynecology, 2018. 132(5): p. 1222-1228.  
15. Print, W.H.O.R.D.B. Novel Coronavirus COVID -19 Therapeutic Trial Synopsis . 2020.  
16. Cella, D., et al., The Patient-Reported Outcomes Measureme nt Information System 
(PROMIS): progress of an NIH Roadmap cooperative group during its first two years.  
Med Care, 2007. 45([ADDRESS_96711] 1): p. S3-S11.  
17. Hays, R.D., et al., PROMIS(¬Æ) -29 v2.0 profile physical and mental health summary 
scores.  Quality of life research : an international journal of quality of life aspects of 
treatment, care and rehabilitation, 2018. 27(7): p. 1885-1891.  
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 57 18. Whitehead, J., Sample size calculations for ordered categorical data.  Stat Med, 1993. 
12(24): p. 2257-71.  
19. Boussinesq, M., et al., Clinical pi[INVESTIGATOR_1103], epi[INVESTIGATOR_88508]-associated 
serious adverse events related to mass ivermectin treatment of onchocerciasis in 
Cameroon.  Filaria journal, 2003. [ADDRESS_96712] 1 (Suppl 1): p. S4-S4.  
20. Makenga Bof, J.C., et a l., Onchocerciasis control in the Democratic Republic of Congo 
(DRC): challenges in a post -war environment.  Trop Med Int Health, 2015. 20(1): p. 48-
62. 
21. Chandler, R.E., Serious Neurological Adverse Events after Ivermectin -Do They Occur 
beyond the Indica tion of Onchocerciasis?  Am J Trop Med Hyg, 2018. 98(2): p. 382-388.  
22. Barkwell, R. and S. Shields, Deaths associated with ivermectin treatment of scabies.  
Lancet, 1997. 349(9059): p. 1144-5.  
23. MERCK & CO., I. TABLETS STROMECTOL (R) (IVERMECTIN) Product Label . 2009  
[cited 2021 February 12]; Available from: 
file:///U:/Personal/My%20Documents/Medical%20Writing/COVID/ACTIV -
6/Study%20Drugs/Ivermectin.pdf.  
24. Nicolas, P., et al., Safety of oral ivermectin during pregnancy: a systematic review and 
meta -analy sis. The Lancet Global Health, 2020. 8(1): p. e92-e100.  
25. Pacqu√©, M., et al., Pregnancy outcome after inadvertent ivermectin treatment during 
community -based distribution.  The Lancet, 1990. 336(8729): p. 1486-1489.  
26. Addiss, D.G., et al., Randomised pl acebo -controlled comparison of ivermectin and 
albendazole alone and in combination for <em>Wuchereria bancrofti</em> 
microfilaraemia in Haitian children.  The Lancet, 1997. 350(9076): p. 480-484.  
27. Dreyer, G., et al., Treatment of bancroftian filariasis i n Recife, Brazil: a two -year 
comparative study of the efficacy of single treatments with ivermectin or diethylcarbamazine.  Trans R Soc Trop Med Hyg, 1995. 89(1): p. 98-102.  
28. Heukelbach, J., S. Franck, and H. Feldmeier, Therapy of tungiasis: a double -blinded 
randomized controlled trial with oral ivermectin.  Mem Inst Oswaldo Cruz, 2004. 99(8): 
p. 873-6.  
29. Martin -Prevel, Y., et al., Tolerance and efficacy of single high -dose ivermectin for the 
treatment of loiasis.  Am J Trop Med Hyg, 1993. 48(2): p. 186-9 2. 
30. Smit, M.R., et al., Safety and mosquitocidal efficacy of high-dose ivermectin when co -
administered with dihydroartemisinin-pi[INVESTIGATOR_88509] (IVERMAL): a randomised, double -blind, placebo-controlled trial.  Lancet Infect 
Dis, 2018. 18(6): p. 615-626.  
31. LLC, E.P., Ivermectin Tablets USP, 7mg, 14mg Investigator's Brochure . 2021.  
32. Yang, S.N.Y., et al., The broad spectrum antiviral ivermectin targets the host nuclear 
transport importin Œ±/Œ≤1 heterodimer.  Antiviral Res, 2020. 177: p. 104760.  
33. Caly, L., et al., The FDA -approved drug ivermectin inhibits the replication of SARS-CoV -
2 in vitro.  Antiviral Research, 2020. 178: p. 104787.  
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 58 34. Lehrer, S. and P.H. Rheinstein, Ivermectin Docks to the SARS -CoV -2 Spi[INVESTIGATOR_88510]-
binding Domain Attached to ACE2.  In Vivo, 2020. 34(5): p. 3023-3026.  
35. Guzzo, C.A., et al., Safety, tolerability, and pharmacokinetics of escalating high doses of 
ivermectin in healthy adult subjects.  Journal of clinical pharmacology, 2002. 42(10): p. 
1122-1133.  
36. Chaccour, C., et al., Ivermectin and COVID -19: Keepi[INVESTIGATOR_88511].  Am 
J Trop Med Hyg, 2020. 102(6): p. 1156-1157.  
37. Arshad, U., et al., Prioritization of Anti-SARS -Cov -2 Drug Repurposing Opportunities 
Based on Plasma and T arget Site Concentrations Derived from their Established Human 
Pharmacokinetics.  Clin Pharmacol Ther, 2020. 108(4): p. 775-790.  
38. Bray, M., et al., Ivermectin and COVID -19: A report in Antiviral Research, widespread 
interest, an FDA warning, two letters to the editor and the authors' responses.  Antiviral 
research, 2020. 178: p. 104805-104805.  
39. Zhang, X., et al., Ivermectin inhibits LPS -induced production of inflammatory cytokines 
and improves LPS-induced survival in mice.  Inflamm Res, 2008. 57(11): p. 524-9.  
40. Ci, X., et al., Avermectin exerts anti -inflammatory effect by [CONTACT_88565] -B and mitogen-activated protein kinase activation pathway.  
Fundam Clin Pharmacol, 2009. 23(4): p. 449-55.  
41. DiNicolantonio, J.J ., J. Barroso -Arranda, and M. McCarty, Ivermectin may be a clinically 
useful anti -inflammatory agent for late -stage COVID -19. Open Heart, 2020. 7(2): p. 
e001350.  
42. Ahmed, S., et al., A five -day course of ivermectin for the treatment of COVID -[ADDRESS_96713] Dis, 2021. 103: p. 214-216.  
43. Chachar, A.Z.K., et al., Effectiveness of Ivermectin in SARS -CoV -2/COVID -19 Patients.  
International Journal of Sciences, 2021.  
44. Abu Taiub Mohammed Mohiuddin, C., et al., Research Square, 2021.  
45. Soto-Becerra, P., et al., Real-World Effectiveness of Hydroxychloroquine, Azithromycin, 
and Ivermectin Among Hospi[INVESTIGATOR_60992] -19 Patients: Results of a Target Trial 
Emulation Using Observational Data from a Nationwide Healthcare System in Peru.  
SSRN Electronic Journal, 2020.  
46. Hashim, H.A., et al., Controlled randomized clinical trial on using Ivermectin with 
Doxycycline for treating COVID -19 patients in Baghdad, Iraq.  medRxiv, 2020: p. 
2020.10.26.20219345.  
47. Ahmed, E., et al., Research Square, 2021.  
48. Khan, M.S.I., et al., Ivermectin Treatment May Improve the Prognosis of Patients With 
COVID -19. Arch Bronconeumol, 2020. 56(12): p. 828-830.  
49. Morgenstern, J., et al., The use of compassionate Ivermectin in the management of 
symptomatic outpatients and hospi[INVESTIGATOR_88512] -19 at 
the Medical Center Bournigal and the Medical Center Punta Cana, Rescue Group, 
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 [ADDRESS_96714] 10, 2020.  medRxiv, 2020: p. 
2020.10.29.20222505.  
50. Krolewiecki, A., et al., Antiviral Effect of High -Dose Ivermectin in Adults with COVID -
19: A Pi[INVESTIGATOR_88513], Controlled, Open Label, Multicentre Trial . 2020, SSRN.  
51. Podder, C.S., et al., Outcome of ivermectin treated mild to moderate COVID -19 case s: a 
single -centre, open -label, randomised controlled study.  IMC Journal of Medical Science, 
2020. 14(2).  
52. Ravikirti, et al., Ivermectin as a potential treatment for mild to moderate COVID -19 ‚Äì A 
double blind randomized placebo -controlled trial.  medRxiv, 2021: p. 
2021.01.05.21249310.  
53. Morteza Shakhsi, N., et al., Research Square, 2021.  
54. Espi[INVESTIGATOR_54604] -Hernandez, G., et al., Effects of Ivermectin -azithromycin -cholecalciferol 
combined therapy on COVID -19 infected patients: A proof of concept study.  Biomedic al 
Research, 2020.  
55. Babalola, O., et al., Ivermectin shows clinical benefits in mild to moderate COVID19: A 
randomised controlled double blind dose response study in Lagos.  medRxiv, 2021: p. 
2021.01.05.21249131.  
56. NIH. COVID -19 Treatment Guidelines Fl uvoxamine . 2021  [cited 2021 April 23]; 
Available from: 
https://www.covid19treatmentguidelines.nih.gov/immunomodulators/fluvoxamine/ . 
57. Apotex, Higlights of Fluv oxamine Maleate Tablets Prescribing Information . 
58. Lenze, E.J., et al., Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients 
With Symptomatic COVID -19: A Randomized Clinical Trial.  JAMA, 2020. 324(22): p. 
2292-2300.  
59. Rosen, D.A., et al., Modulation of the sigma-1 receptor ‚ÄìIRE1 pathway is beneficial in 
preclinical models of inflammation and sepsis.  Science Translational Medicine, 2019. 
11(478): p. eaau5266.  
60. Rafiee, L., V. Hajhashemi, and S.H. Javanmard, Fluvoxamine inhibits some inflammatory 
genes expression in LPS/stimulated human endothelial cells, U937 macrophages, and 
carrageenan-induced paw edema in rat.  Iran J Basic Med Sci, 2016. 19(9): p. 977-984.  
61. Seftel, D. and D.R. Boulware, Prospective Cohort of Fluvoxamine for Early Treatm ent of 
Coronavirus Disease 19.  Open Forum Infectious Diseases, 2021. 8(2). 
62. GlaxoSmithKline, Highlights of Prescribing Information for Arnuity Ellipta . 2018: 
Online.  
63. Yamaya, M., et al., Inhibitory effects of glycopyrronium, formoterol, and budesonide on 
coronavirus HCoV -229E replication and cytokine production by [CONTACT_88566][INVESTIGATOR_1663].  Respir Investig, 2020. 58(3): p. 155-168.  
64. Peters, M.C., et al., COVID -19-related Genes in Sputum Cells in Asthma. Relations hip to 
Demographic Features and Corticosteroids.  Am J Respir Crit Care Med, 2020. 202(1): p. 
83-90.  
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 60 65. Finney, L.J., et al., Inhaled corticosteroids downregulate the SARS-CoV -2 receptor ACE2 
in COPD through suppression of type I interferon.  J Allergy Clin  Immunol, 2021. 147(2): 
p. 510-519.e5.  
 
  
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 61 16. Appendix A ‚Äì Iver mectin  
16.1. Risk Assessment  
The most commonly reported adverse events for ivermectin are pruritus (25.3%), headache 
(13.9%), and dizziness (7.5%) (ICH working group, 2003). Since the 1980s, the use of 
ivermectin in humans for the treatment of filariasis, especially onchocerciasis, has been 
associated with SAEs, including coma, seizure and death only when administered in regions where onchocerciasis  and loiasis  are co -endemic . [19] 
The issue of SAEs due to ivermectin is a threat to adherence to mass drug administration and the control and elimination of disease  in communities co-endemic with  O. volvulus  and Loa loa. 
Mass drug administration were suspended from 2004 to 2006 in some health zones in the 
Equateur, Bas Congo, and Oriental provinces in the D emocratic Republic of the Congo because 
of ivermectin -associa ted SAEs in the Bas Congo and Oriental provinces in 2003.  [20] It has been 
thought that c o-infection with L. loa  is a risk factor for the development of these reactions.  [21] 
Additionally, a study investigating escalating high doses of ivermectin in healthy adults was 
performed to explore the safety of its use in the treatment of head lice. The authors documented 
no evidence of CNS toxicity in doses up to [ADDRESS_96715] FDA -approved dose of 200 
¬µg/kg.  [22] 
Table 3 shows safety events that occurred in greater than 5% of the clinical trial population who 
received ‚â• 300 ¬µg/kg of ivermectin.  [23]  For a detailed list of the adverse reactions that occurred 
during clinical trials with ivermectin, refer to the product label  and the Investigator‚Äôs Brochure . 
Ivermectin is pregnancy category C and is not contraindicated per FDA. Analys es of outcomes 
of pregnancies in women inadvertently exposed to ivermectin through mass administration 
campaigns show no evidence of increased birth defects, neonatal deaths, maternal morbidity, 
preterm births, or low birthweight over baseline rates. [24, 25]  
Table 3: Ivermectin Adverse Event Table  for Doses ‚â•  300 ¬µg/kg 
Indication (dose)  
Wuchererua bancrofti  
(200 -400 ¬µg/kg)  [26] 
Wuchererua bancrofti  
(200 ¬µg/kg, then 400 
¬µg/kg on day 4)  [27] 
Stage II or III tungiasis 
lesions (300 ¬µg/kg, 
days 1 & 2)  [28]  
Loa loa  infection (300 
or 400 ¬µg/kg)  [29] 
Symptomatic 
Plasmodium 
falciparum  malaria 
(600 ¬µg/kg)  [30] 
Adverse Reaction s 
Abdominal Pain    7%   
Cough  42%     
Diarrhea     6.5%   
Eye disorders      9% 
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 62 Fever  69% 46%  8%  
Gastrointestinal   18%    
Headache  75%  11% 16%  
Local Inflammation   9%    
Local Pain   9%    
Lumber myalgia     6.5%   
Malaise   27%    
Myalgia  37%     
Neurological   15%    
Pneumonia      9% 
Pruritus     60%  
Renal   33%    
Respi[INVESTIGATOR_696]   33%    
16.2. Additional Appendix -Level Exclusion Criteria  
1. End-stage renal disease on renal replacement therapy  
2. Liver failure  or decompensated cirrhosis  
3. Use of warfarin , CYP3A4, P -gp inhibitor drugs, or CYP3A4 substrates  (see Section 
16.2.1) 
4. Nursing mothers  
5. Pregnancy*  
*Participants must agree to use an effective method of contraception during study drug 
administration and for at least 3 days after their final dose of study drug.  Effective methods 
include any of the following: abstinence, partner vasectomy, bilateral tubal ligation, intrauterine 
device, progestin implants, or barrier (condom, diaphragm, cervical cap) plus spermicide.  
16.2.1.  Precautions  
While rare, post -marketing reports indicate an increased International Normalized Ratio (INR) 
when ivermectin was co -administered with warfarin.  With a 3 -day dosing period this is unlikely 
to be a significant issue , but INR monitoring can be recommended to the care provider if felt 
warranted by [CONTACT_88567] .   
Use of CYP3A4  inducers and inhibitors and P-gp inhibitor are contraindicated for use with 
ivermectin.  
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 [ADDRESS_96716]-spectrum, anti -parasitic agents isolated from Streptomyces avermitilis  
fermentation products.  It binds selectively, and with high affinity, to glutamate -gated chloride 
ion channels, therefore increasing cel l membrane permeability to chloride ions resulting in death 
of the parasite.  [31] It is currently FDA -approved for the foll owing indications: st rongyloidiasis 
of the intestinal tract due to the nematode parasite Strongyloides stercoralis  and onchocerciasis 
due to the nematode parasite Onchocerca volvulus . [23] Per the FDA -approved labelling of 
ivermectin, the recommended dose is 200 ¬µg/kg/day to treat strongyloidiases and 150 ¬µg/kg/day 
to treat onchocerciasis in the form of a 3 mg tablet.    
16.3.1.  Formulation, Appearance, Packaging, and Labeling  
Ivermectin is a white to yellowish -white, nonhygroscopic, crystalline pow der. For this study, 
ivermectin will be supplied as fifteen 7-mg tablets in a bottle  with a single panel label . The 
tablets are white, round, biconvex tablets with ‚Äú123‚Äù over the scoring on one side. All packaging 
will be labeled to indicate that the product is for investigational use.  
16.3.2.  Drug Dispensing, Storage, and Stability  
Ivermectin will be supplied as 7-mg tablets and must be stored at temperatures below 30¬∞C.  
16.3.3.  Dosing and Administration 
Ivermectin should be taken on an empty stomach with water  (30 minute s before a meal or 2 
hours after a meal). Each participant will receive a bottle of fifteen  7-mg tablets and will be 
instructed to take a pre -specified number of tablets for 3 consecutive days based on their weight 
(see Table 4) for a daily dose of approximately 300-400 ¬µg/kg.  
Table 4: Ivermectin Dosing Schedule  
Weight (kg)  Day 1 (# of 7 -
mg tablets)  Day 2 (# of 7 -
mg tablets)  Day 3 (# of 7 -
mg tablets)  Daily Dose  
(¬µg/kg)  
35-52 2 2 2 269-400 
53-69 3 3 3 304 -396 
70-89 4 4 4 315-400 
>90 5 5 5 ‚â§389 
16.3.4.  Rationale for Selection of Dose  
Pre-clinical studies:  
Reports from in vitro  studies suggest that ivermectin acts against RNA viruses such as SARS -
CoV-[ADDRESS_96717] importin Œ±/Œ≤ -mediated nuclear transport that prevent viral proteins 
from entering the nucleus to alter host cell function.  [32] A single dose addition of ivermectin to 
Vero -hSLAM cells [ADDRESS_96718] a 5000 -fold 
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 64 reduction in viral RNA at 48 hours  and may interfere with the att achment of SARS-CoV -2 spi[INVESTIGATOR_88514].  [33, 34]  
Ivermectin has been shown to inhibit the replication of SARS -CoV -[ADDRESS_96719] that ivermectin doses up to 100-fold 
higher than those approved for use in humans would be required to achieve the plasma 
concentrations necessary to duplicate the drug‚Äôs antiviral efficacy in vitro . [35, 36]  Even though 
ivermectin appears to accumulate in lung tissue, with the doses used in most clinical trials, predicted system ic plasma and lung tissue concentrations are much lower than 2 ¬µM, the half -
maximal inhibitory concentration (IC
50) against SARS -CoV -2 in vitro . [37, 38]  
Ivermectin demonstrates potential anti -inflammatory properties in some in vitro  
studies,  properties which have been postulated to be beneficia l in the treatment of COVID -19. 
[39-41]  The dose range for an anti -inflammatory effect may be lower than for the anti -viral 
effects.  [41]   
Clinical studies:  
A number of retrospective cohort studies and the results of several randomized trials of 
ivermectin use in patients with COVID -[ADDRESS_96720] been published in peer -reviewed journals or 
made available as preliminary, non -peer -reviewed reports. S ome clinical studies showed no 
benefits after ivermectin use, whereas others reported shorter time to resolution of disease 
manifestations attributed to COVID -19, greater reduction in inflammatory markers,  shorter time 
to viral clearance,  or lower mortalit y rates in patients who received ivermectin than in patients 
who received comparator drugs or placebo.  [42-48] 
Most of the studies reported to date are limited by [CONTACT_88568], varying dosing schedules and the adjunctive use of various concomitant medications  (e.g., doxycycline, 
hydroxychloroquine, azithromycin, zinc, corticosteroids), confounding assessment of the true 
efficacy or safety of ivermectin.  Clinical studies in outpatients with COVID -[ADDRESS_96721] clinical trials of outpa tients with 
mild/moderate COVID -[ADDRESS_96722] shown clinical improvement with even a single dose
 or a short 
two to five -day cours e of ivermectin given orally shortly after symptom onset.  [36, 46, 49, 50]   
There is a dose -dependent relationship between i vermectin dos e and clinical efficacy. Trials 
using lower doses of i vermectin  tend to show no or minimal clinical benefit in COVID -19 
patients treated in the outpatient or hospi[INVESTIGATOR_6885].  [51, 52]  Higher doses, at least 0.4 mg/kg, 
particularly when administered in multiple doses , have been shown to significantly reduce time 
to recovery and mortality as compared with lower  doses or placebo/standard care . [49, 53-55]  
There is a concentration -dependent virologic response seen using higher -than-usual doses of 
ivermectin (600 Œºg/kg vs. 200 Œºg/kg once daily for 5 days)  that have been shown to significant ly 
reduc e the time to PCR viral positivity over standard doses with minimal associated toxicities.  
[50]  
The safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin was tested 
in healthy adult subjects . [35] Doses from 30 mg/day (347-571 ¬µg/kg)  to 120 mg/day (1404-
2000 ¬µg/kg) given for 3 days were all well tolerated . [35] These data coupled with evidence of 
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 65 superior clinical efficacy of doses in the lower of this range provide the rationale for the 300-400 
¬µg/kg dose given f or 3 days in the proposed trial.  
16.4. Placebo Informati on  
16.4.1.  Formulation, Appearance, Packaging, and Labeling  
Placebo will match the appearance of  the 7-mg ivermectin tablets: white, round, biconvex tablets 
with ‚Äú123‚Äù over the scoring on one side . A total of fifteen  tablets will be  provided in a  bottle  
with a single panel label . The placebo formulation includes the following ingredients in a 210 mg 
tablet: microcrystalline cellulose, NF (MC-102; pregelatinized s tarch, NF  (Starch 1500) ; 
croscarmellose s odium, NF  (Vivasol, GF Grade) ; colloidal silicon d ioxide, NF  (Aerosil 200)  and 
magnesium s tearate, NF (2257) . All packaging will be labeled to indicate that the product is for 
investigational use.  
16.4.2.  Drug Dispensing, Storage, and Stability  
Placebo must be stored at temperatures below 30¬∞C.  
16.4.3.  Dosing and Administr ation  
Dosing and administration will occur according to Section 16.3.[ADDRESS_96723]  
None  
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 66 17. Appendix B ‚Äì Fluvoxamine maleate  
17.1. Risk Assessment  
The most common adverse effects of fluvoxamine described in the setting of  treatment of 
psychiatric conditions include gastrointestinal effects, neurological effects, dermatological 
reactions, and in rare cases suicidal ideation.  [56] In two 10-week controlled trials in Obsessive 
Compulsive Disorder (OCD) and depression at doses ranging from 100-300 mg/day, the most commonly observed adverse reactions associated with the use of fluvoxamine maleate tablets 
(incidence of 5% or greater an d at least twice that for placebo) were nausea, somnolence, 
insomnia, asthenia, nervousness, dyspepsia, abnormal ejaculation, sweating, anorexia, tremor, 
and vomiting  (see Table 5). [57]  Table 6 lists the complete set of adverse events identified in a 
randomized clinical trial of fluvoxamine (300 mg/day for 15 days) versus placebo in 152 
COVID -19 participants. [58] Adverse events and serious adverse events were more common in 
the placebo arm and the single SAE in the fluvoxamine  arm was dehydration and the study 
medication was not interrupted.  [58]  
Table 5. Fluvoxamine Adverse events occur ring in 10 -week studies of adult OCD or 
depression 
 *Table shows events that  occurred in ‚â• 5% of adult OCD and depression study 
participants receiving 100-300 mg/day for 10 weeks of fluvoxamine maleate versus 
placebo. [57] 
Adverse Reaction  Fluvoxamine, 
n=892 (%)  Placebo, 
n=778 (%)  
Headache  22 20 
Asthenia  14 6 
Nausea  40 14 
Diarrhea  11 7 
Constipation  10 8 
Dyspepsia  10 5 
Anorexia  6 2 
Vomiting  5 2 
Somnolence  22 8 
Insomnia  21 10 
Dry Mouth  14 10 
Nervousness  12 5 
Dizziness  11 6 
Tremor  5 1 
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 67 Anxiety  5 3 
 
Table 6. Fluvoxamine Adverse events that occurred in COVID -19 study participants 
receiving 300 mg/day for 15 days.  
Adverse Reaction  [58] 
 Fluvoxamine, n=80  
(%) Placebo, n=72 
(%) 
Pneumonia  3.[ADDRESS_96724] pain or tightness  0 2.8 
Fever  0 2.8 
Acute respi[INVESTIGATOR_1399]  0 1.4 
Serious adverse events  1.3 6.9 
Other adverse events  13.8 8.3 
17.2. Additional Appendix -Level Exclusion Criteria  
1. Use of selective serotonin  (or norepi[INVESTIGATOR_238])  reuptake inhibitors (SSRIs/SNRIs) 
or monoamine oxidase inhibitors (MAOIs) within 2 weeks of consent including 
triptans and tryptophan  
2. Co-administration of tizanidine, thioridazine, alosetron, pi[INVESTIGATOR_3924], diazepam, 
ramelteon  
3. Nursing mothers  
4. Pregnancy* 
*Part icipants must agree to use an effective method of contraception during study drug 
administration and for at least 3 days after their final dose of study drug. Effective methods 
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 68 include any of the following: abstinence, partner vasectomy, bilateral tubal li gation, intrauterine 
device, progestin implants, or barrier (condom, diaphragm, cervical cap) plus spermicide.  
17.2.1.  Precaution s 
Fluvoxamine is a potent inhibitor of CYP1A2 and 2C19 and a moderate inhibitor of CYP2C9, 
2D6, and 3A4, as such, it may enhance antic oagulant effects of antiplatelets and anticoagulants 
as well as other medications. It is recommended that concomitant medications listed below be 
discussed with participants and potential effects of increased drug exposure reviewed and monitored by [CONTACT_88569]/or their prescribing clinician.  
‚Ä¢ Tricyclic antidepressants: monitor for side effects with amitriptyline, clomipramine, 
imipramine  
‚Ä¢ Antipsychotic drugs: neuroleptic malignant syndrome or similar; particularly 
clozapi[INVESTIGATOR_050] (hypotension, seizure)  
‚Ä¢ Benz odiazepi[INVESTIGATOR_1651]:  particularly alprazolam; recommend dose reduction  
‚Ä¢ Methadone: opi[INVESTIGATOR_9845] 
‚Ä¢ Mexiletine: monitor for side effects  
‚Ä¢ Theophylline: recommend dose reduction and monitor for side effects  
‚Ä¢ Warfarin: monitor INR 
‚Ä¢ NSAIDS or aspi[INVESTIGATOR_248]: monitor for si gns of bleeding 
‚Ä¢ Diltiazem, propranolol, metoprolol: monitor for bradycardia  
Participants should be warned about fluvoxamine inhibition of caffeine metabolism. A 
description is 1 cup of coffee has the effects of 4 cups  while taking fluvoxamine .  
Caution should be used in participants with hepatic dysfunction due to approximately 30% increase in exposures .  
17.3. Fluvoxamine  Information  
Fluvoxamine is an FDA -approved SSRI for the treatment of OCD . Clinically it is also used for 
other conditions such as depression. [56] The active ingredient in fluvoxamine is fluvoxamine 
maleate.  
17.3.1.  Formulation, Appearance, Packaging, and Labeling  
Fluvoxamine is a round golden 50 mg tablet that is scored on both sides - one side has ‚ÄúAPO‚Äù 
and the other side has ‚ÄúF50‚Äù with a partial bisect. All packaging will be labeled to indicate that 
the product is for investigational use.  
17.3.2.  Drug Dispensing, Storage, and Stability  
Drug will be supplied by [CONTACT_88570]. Study drug should be 
stored in controlled room temperature (20 ¬∞C to 25¬∞C) ; excursions are permitted to 15¬∞C to 30¬∞C.  
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 69 17.3.3.  Dosing and Administration 
Fluvoxamine will be self -administered orally by [CONTACT_88571] a dose of 50 mg BID for 10 
days.  
17.3.4.  Rationale for Selection of Dose  
The recommended starting dose of fluvoxamine for OCD  in adults is 50 mg daily dose to be 
titrated up to a maximum of 300 mg/day divided into BID doses. Clinical data from the placebo-
controlled, randomized trial in nonhospi[INVESTIGATOR_88515] -19 demonstrated that a 
50 m g BID fluvoxamine dose was well -tolerated and effective (see Figure 4).[58] In the same 
study, doses of 100 mg BID in COVID -19 participants resulted in additional side effects  over a 
14-day period. The 300 mg daily dose is for serotonin receptor activity, whereas the postulated 
dose for sigma -1 receptor activity as an anti -inflam matory is lower.  Therefore, the proposed 
dosing regimen of 50 mg BID for 10 days will use the anticipated minimal effective dose to 
maximize efficacy and minimize toxicity.  
Pre-Clinical Studies : 
Pre-clinical studies have indicated that the anti -inflammator y effects of fluvoxamine may support 
its use for treating COVID -19. Systemic inflammation as a result of infection can damage 
vasculature which may lead to tissue hypoperfusion and multiple organ failure. [59] Reducing 
systemic inflammation thereby [CONTACT_88572]. In murine studies, administration of fluvoxamine significantly increased survival of 
S1R wildtype (WT) mice and S1R knockout (KO) mice challenged with ligand 
lipopolysaccharide (LPS) as compared to mice that received saline ( Figure 3).[59] Fluvoxamine 
also reduced production of inflammatory cytokines in ex vivo  and in vitro  murine and human 
cells (HEK293mTLR4/MD2/CD14, primary lung fibroblasts, and mouse bone marrow -derived 
macrophages) and inflammatory genes in human endothelial cells. [59, 60]  
 
Figure 3: Survival curve of WT and S1R KO mice  
Figure note: Mice were treated with vehicle (33% Kolliphor in saline) or STF (30 mg/kg) after 
administration of LPS (2 mg/kg) as indicated in (B) (n = 15 to 16 mice per group; **P < 0.01, ***P < 0.001, log-rank test). [59] 

CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 70 Clinical Studies : 
A placebo -controlled, randomized trial in nonhospi[INVESTIGATOR_88515] -19 tested the 
efficacy and safety of fluvoxamine (50 mg oral one -time dose, followed by 100 mg orally twice 
daily for 2 days, followed by 100 mg orally three  times daily through day 15) versus placebo 
[58]. Results of the study reported that 8.3% (6/72) of participants who received placebo 
experienced clinical deterioration within 15 days of randomization, as opposed to 0% (0/80) in 
the fluvoxamine arm (absolute difference 8.7%; 95% CI, 1.8% to 16.5%;  P = 0.009) .[58]  
Clinical deterioration was  defined as shortness of breath/pneumonia with hypoxia  (Figure 4). 
Concomitant SSRI/SNRI dosing was not allowed per the trial protocol thus the participant‚Äôs 
SSRI/SNRI was held for the study dosing period if reported at baseline .  
 
Figure 4: Summary of JAMA Randomization Clinical Trial of Fluvoxamine for Early 
COVID-19.   
A prospective, nonrandomized observational cohort study that evaluated fluvoxamine showed that on Day 14, 0/65 participants had persistent symptoms as opposed to 19/48 participants who 
did not receive fluvoxamine (P < 0.001)  [61]. Additionally, by [CONTACT_2006] 14, none of the participants 
who received fluvoxamine were hospi[INVESTIGATOR_88516] 6 participants who were 
hospi[INVESTIGATOR_88517] (see Figure 5). In this study, all participants were 
offered fluvoxamine and decided whether or not to take the study drug. Participants who chose to 
receive th e study drug received 50 mg of fluvoxamine two time s a day following an upfront 100 
mg loading dose. [61]  

CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 71  
Figure 5: Summary of study results for the prospective, nonrandomized observational 
cohort study with fluvoxamine in participants diagnosed with COVID -19.  
17.4. Placebo Information  
The placebo will be a fluvoxamine -matched placebo containing mannitol, magnesium stearate, 
hydroxyethyl cellulose, polyethylene glycol, titanium dioxide, yellow ferric oxide, and purified 
water . The appearance and packaging will match that of the study drug (as described in Section 
17.3.1). All packaging will be labeled to indicate that the product is for investigational use .  
17.4.1.  Formulation, Appearance, Packaging, and Labeling  
Placebo will match the appearance of the fluvoxamine tablets: round golden 50 mg tablet that is 
scored on both sides - one side has ‚ÄúAPO‚Äù and the other side has ‚ÄúF50‚Äù with a partial bisect. All 
packaging will be labeled to indicate that the product is for investigational use.  
17.4.2.  Drug Dispensing, Storage, and St ability  
Placebo  will be supplied by [CONTACT_88570]. Placebo  should be 
stored in controlled room temperature (20¬∞C to 25¬∞C).  
17.4.3.  Dosing and Administration 
Participants  will self-administer  one placebo tablet orally , twice daily for [ADDRESS_96725]  
None  
 

CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 72 18. Appendix C ‚Äì Arnuity Ellipta (fluticasone furoate inhalation powder)  
18.1. Risk Assessment  
The most common adverse reactions reported in ‚â• 5% of adults and adolescents  with lung 
disease  include nasopharyngitis, bronchitis,  upper respi[INVESTIGATOR_1092], and headache. 
Long-term use of systemic and local corticosteroid s may also result in the following side effects: 
Candida albicans  infection, immunosuppression, hypercorticism and adrenal suppression, 
reduction in bone mi neral density (BMD), or glaucoma and cataracts.  [62] 
There are insufficient data on the use of A rnuity Ellipta in pregnant women. There are clinical 
considerations with use of A rnuity Ellipta in pregnant women to inform drug-associated risk  and 
benefit . In animal reproduction studies, fluticasone furoate administered by [CONTACT_88573]. The 
highest fluticasone furoate doses in the rat and rabbit studies were 4 times and 1 times the 
maximum recommen ded human daily i nhalation dose, respectively. The estimated risk of major 
birth defects and miscarriage for the indicated populations is unknown. In the US general population, the estimated risk of major birth defects and miscarriage in clinically recognized pregnancies i s 2% to 4% and 15% to 20%, respectively.  [62] 
Disease -Associated Maternal and/or Embryofetal Risk: In women with poorly or moderately 
controlled asthma, there is an increased risk of several perinatal outcomes such as pre-eclampsia 
in the mother and prematurity, low birth weight, and small for gestational age in the neonate.  
[62]  
Table 7. Fluticasone Adverse reactions that occurred in ‚â•3% of adults and adolescents 
with asthma in a 24 -w eek tr ial . 
 
Adverse Reaction  [62] Arnuity Ellipta ,  
fluticasone  200 ¬µg, n=119 
(%) Arnuity Ellipta , 
fluticasone  100 ¬µg, 
n=119 (%)  
Nasopharyngitis  [ADDRESS_96726] infection 6 2 
Sinusitis  4 7 
Oropharyngeal pain  4 3 
Pharyngitis  3 6 
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 73 Back pain  3 3 
Dysphonia  3 2 
Oral candidiasis  3 <1 
Procedural pain 3 <1 
Rhinitis  3 <1 
Throat irritation  3 <1 
Abdominal pain 3 0 
Cough 3 0 
18.2. Additional Appendix -Level Exclusion Criteria  
1. Severe hypersensitivity to milk proteins  
2. Currently prescribed or use within 30 days of inhaled or systemic steroids  
3. Liver failure  
4. Nursing mothers  
5. Pregnancy* 
*Participants must agree to use an effective method of contraception during study drug 
administration and for at least 3 days after their final dose of study drug. Effective methods 
include any of the following: abstinence, partner vasectomy, bilateral tubal ligation, intrauterine 
device, progestin implants, or barrier (condom, diaphragm, cervical cap) plus spermicide.  
18.2.1.  Precautions  
While not contraindicated, the following should be considered while taking Arnuity Ellipta:  
‚Ä¢ Strong cytochrome P450 3A4 inhibitors (e.g. ketoconazole, ritonavir, clarithromycin, 
conivaptan, indinavir, itraconazole, lopi[INVESTIGATOR_054], nefazodone, nelfinavir, saquinavir, 
telithromycin, troleandomycin, voriconazole) should be used with caution as 
increased systemic corticosteroid adverse effects may occur in combination with 
Arnuity Ellipta. Generally, due to the limited study drug administration length, 
clinically significant interactions are unlikely.  
‚Ä¢ Paradoxical Bronchospasm may occur with an immediate increase in wheezing after 
dosing. Ar nuity Ellipta should be discontinued immediately if this occurs.  
‚Ä¢ Fluticasone furoate systemic exposures may be increased in participants with hepatic 
impairment thus use with caution in participants with moderate to severe hepatic 
impairment  
  
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 74 18.3. Arnuity Ell ipta Information  
Arnuity Ellipta is the brand name [CONTACT_88575] [CONTACT_35316]. 
It is a synthetic trifluorinated inhaled corticosteroid ( ICS) with anti -inflammatory activity. In 
vitro  and in vivo  models have shown that flut icasone furoate demonstrates anti -inflammatory 
actions by [CONTACT_88574], inhibiting pre -inflammatory 
transcription factors such as NFkB, and inhibiting antigen-induced lung eosinophilia, which may contribute to its efficacy  in the approved indications. It is FDA -approved for once -daily 
maintenance treatment of asthma as prophylactic therapy in patients 5 years and older.  [62]  
18.3.1.  Formulation, Appearance, Packaging, and Labeling  
Arnuity Ellipta is an inhaled powder drug product composed of fluticasone furoate. Fluticasone furoate is a synthetic trifluorinated corticosteroid that is insoluble in water. Fluticasone furoate is 
a white powder. Arnuity Ellipta will be provided in a two tone gr ey inhaler with a  mouthpi[INVESTIGATOR_88518]. The blister strips used for this study will contain a white 
powder mix with a mixture of 200 ¬µg micronized fluticasone furoate and lactose monohydrate. 
The inhaler will be package d in a moisture -protective foil tray with a desiccant and a peelable 
lid. [62] All packaging will be labeled to indicate that the product is for investigational use.  
18.3.2.  Drug Dispensing, Storage, and Stability  
The study drug should be stored at room temperature (20¬∞C  to 25¬∞C) with excursions permitted 
from 15¬∞C to 30¬∞C. It should be stored in a dry environment away from direct heat or sunlight. 
Unopened Arnuity Ellipta should be stored inside the unopened moisture -protective foil tray and 
only removed immediately before use. Any unused study product should be dis carded 6 weeks 
after opening the foil tray or when the counter reads ‚Äú0‚Äù (after all blisters have been used), 
whichever comes first. The inhaler is not reusable .[62] The study product has a shelf life of 24 
months when stored at ‚â§ 25¬∞C. After removal of the secondary package and the desiccant packet 
from the inhaler, the product may be stored up to 6 weeks at ‚â§ 25¬∞C.  
18.3.3.  Dosing and Administration 
Arnuity Ellipta is a self -administered inhaled drug. Participants will se lf-administer 200 ¬µg ( 1 
blister) of Arnuity Ellipta once daily for 14 days. After inhaler activation, the powder within the 
blister is exposed and the participant inhales the study drug through the mouthpi[INVESTIGATOR_13959].  
18.3.4.  Rationale for Selection of Dose  
Inhaled corti costeroids (ICS) have been shown to be effective in improving asthma and as a 
combination therapy in chronic obstructive pulmonary disease (COPD) and thus are commonly 
prescribed medications world-wide. Corticosteroids have been shown to have a broad range  of 
pharmacologic activity on multiple cell types including mast cells, eosinophils, neutrophils, 
macrophages and lymphocytes, as well as other mediators of inflammation such as histamine, 
eicosanoids, and leukotrienes. In addition to the anti -inflammatory  role of ICS, there is also 
potential for regulation of gene transcription in epi[INVESTIGATOR_1663]. [63-65]  This regulation of gene 
transcription may result in inhibition of SARS -CoV -2 replication. Furthermore, in asthmatic 
patients , ICS may lower gene expression of ACE2 and TMPRSS2. T he ACE2 receptor is 
expressed on epi[INVESTIGATOR_88519]-CoV -2 for entry and the serine protease T MPRSS2 
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 75 primes the SARS -CoV -2 spi[INVESTIGATOR_88520]. Lowering gene expression of ACE2 and 
TMPRSS2 may reduce binding and entry into cells therefore reducing or preventing infection.  
Clinical Studies:  
The PRINCIPLE (Platform Randomized trial of Interven tions against COVID -19 in Older 
People) trial is a multicenter, open -label, multi-arm, adaptive randomized, platform trial. The 
trial is ongoing and released an interim analysis after the Trial Steering Committee advised the 
Trial Management Group that the  pre-specified superiority criterion was met on the time to 
recovery in the overall study population and the subgroup of participants with confirmed positive 
SARS-CoV -2 testing. Participants were eligible if aged >65 years, or > [ADDRESS_96727] 14 days. Participants were randomized to any open active 
intervention arm including inhaled budesonide and usual care. Participants were followed 
through an online, daily symptom diary for 28 days. Participants received usual care plus inhaled 
budesonide 800 ¬µg daily for 14 days or usual care alone. The primary outcome of the trial at the 
start was hospi[INVESTIGATOR_88521] 28 days; however, the ra te of hospi[INVESTIGATOR_88522] a measure of illness duration. The trial 
was completed with two co-primary endpoint s measured within 28 days of randomization: 1) 
time to first reported recovery defined as the first day that a participant reported feeling 
recovered; and 2) hospi[INVESTIGATOR_88523] -19.  
The interim analysis included eligible SARS -CoV -2 positive participants who were randomized 
to inhaled budesonide (N=751) or usual care alone (N=1028). The mean age was 62.8 years and 83% of participants had co-morbidities. The median days from symptom onset to enrollment was 
[ADDRESS_96728]-recovery in the budesonide arm with an 
estimated median benefit of 3 days. The point estimate of the proportion of COVID -19 related 
hospi[INVESTIGATOR_88524] (8.5%) versus usual care (10.3%), 
but this did not meet statistical significance (95% BCI -0.7 ‚Äì 4.8%). There were two SAE s for 
hospi[INVESTIGATOR_88525] -19, both in the budesonide group.  
A smaller trial of 146 nonhospi[INVESTIGATOR_88515] -19 reported that inhaled 
budesonide at the same dose reduced COVID -19 related emergency assessments and 
hospi[INVESTIGATOR_059].  
The dose of ICS studied is PRINCIPLE is consistent with a high dose of inhaled steroid. The equivalent high dose of Arnuity Ellipta  is 200 ¬µg/day. Inhaled fluticasone furoate has a greater 
anti-inflammatory potency per microgram than budesonide, thus fluticasone furoate is 
administered at a lower daily dose and used only once daily to achieve a similar high dose.  
18.4. Placebo Information  
18.4.1.  Formulation, Appearance, Packaging, and Labeling  
The placebo will be an Arnuity Ellipta -matched placebo containing lactose for inhalation in the 
same two tone grey inhaler  that is used for the study drug. The appearance and packaging will 
match that of the study drug (as described in Section 18.3.1). All packaging will be labeled to 
indicate that the product is for investigational use.  
CONFIDENTIAL  ACTIV -6 Protocol [v2.0] 
 
 76 18.4.2.  Drug Dispensing, Storage, and Stability  
Placebo will be s tored in the same conditions as study drug, room temperature (20¬∞C to 25¬∞C) 
with excursions permitted from 15¬∞C to 30¬∞C in a dry environment away from direct heat or 
sunlight.  The placebo has a shelf life of up to 36 months when stored at ‚â§ 30¬∞C.  
18.4.3.  Dosing an d Administration 
Participants will self -administer one blister of placebo via inhalation from the inhaler once daily 
for [ADDRESS_96729]  
None  
18.6. Safety Reporting for Arnuity Ellipta  
Sponsor will promptly notify G laxoSmit hKline of all SAEs, UADEs,  and pregnancies (if 
applicable), and medical device deficiencies that have occurred for participants enrolled in this 
Study Drug Appendix, in accordance with the timelines and procedures specified in the 
Protocol/appendix. In addition, the sponsor will reasonably obtain and provide follow -up 
information as available, to [COMPANY_004] upon request.  
 
 
 